Category: Articles

Current Trends in Chronic Wound and Scar Management: A Comprehensive Review

A recent review published in Wound Management & Prevention by Drs. Chantalle Crous, Judey Pretorius, and Anél Petzer offers a detailed examination of contemporary approaches to managing chronic wounds and pathological scars. The article underscores the complexity of these conditions and the necessity for multifaceted treatment strategies. :contentReference[oaicite:5]{index=5}

Key Highlights:

• Multiphase Healing Process: The review outlines the four overlapping phases of wound healing—hemostasis, inflammation, proliferation, and remodeling—and discusses how disruptions in these phases can lead to chronic wounds.
• Scar Formation Challenges: It emphasizes that while scar tissue is a natural part of healing, excessive or pathological scarring can cause significant physical and psychological distress, highlighting the need for effective management strategies.
• Emerging Therapies: The authors discuss various treatment modalities, including advanced dressings, growth factor therapies, and stem cell applications, noting that while these show promise, further research is needed to establish their efficacy and safety.

The review concludes that despite the availability of numerous treatment options, there is no universally accepted gold standard for managing chronic wounds and scars. The authors advocate for continued research into the molecular mechanisms of wound healing and scarring to develop more effective and targeted therapies.:contentReference[oaicite:16]{index=16}

Read the full article on the HMP Global Learning Network website.

Keywords:
chronic wounds,
scar management,
wound healing,
Chantalle Crous,
Judey Pretorius,
Anél Petzer

Upcoming Webinar: Latest Advances in NPWT and Algorithmic Wound Management

On Wednesday, June 11, 2025, at 1:00 PM ET, HMP Global will host a webinar titled “Latest Advances in the World of NPWT: Defining an Algorithmic Framework for Wound Management Throughout the Transition of Care”. This 60-minute session, sponsored by Solventum, aims to equip healthcare professionals with the latest insights into negative pressure wound therapy (NPWT) and its application across various care settings. :contentReference[oaicite:5]{index=5}

Key Highlights:

• Algorithmic Decision-Making: Attendees will learn streamlined strategies to select appropriate NPWT options, facilitating patient transitions across the continuum of care.
• Practical Application Tips: The session will provide guidance on wound characteristics and recommendations for utilizing NPWT technologies, including the 3M™ V.A.C.® Peel and Place system.
• Evidence-Based Insights: The webinar will highlight published data supporting the efficiency and cost-effectiveness of Solventum’s NPWT solutions.

This educational event is designed for clinicians seeking to enhance their wound management practices through evidence-based NPWT applications. The session will conclude with a Q&A segment to encourage interactive discussion and address participant queries.:contentReference[oaicite:16]{index=16}

Register for the webinar on the HMP Global website.

Keywords:
NPWT,
wound management,
Solventum,
Ralph J. Napolitano

Storied Careers: A Conversation with Prof. David Armstrong on Diabetic Limb Preservation

In a recent interview featured on Diabetic Foot Online, Professor David G. Armstrong of the Keck School of Medicine at USC reflects on his journey in podiatric surgery and his mission to prevent diabetic foot amputations. As a leading figure in limb preservation, Dr. Armstrong discusses the evolution of his career, the importance of interdisciplinary collaboration, and his vision for the future of diabetic foot care.:contentReference[oaicite:4]{index=4}

Key Highlights:

• Early Inspiration: Growing up with his father, renowned podiatrist Leo N. Armstrong, David was inspired by the immediate impact podiatric care could have on patients. This early exposure laid the foundation for his commitment to the field.
• Team-Based Approach: Dr. Armstrong emphasizes the “toe and flow” philosophy, advocating for a collaborative approach that combines podiatric and vascular expertise to enhance patient outcomes in limb preservation.
• Educational Influence: His training at the California College of Podiatric Medicine instilled a culture of interdisciplinarity, shaping his perspective on the importance of teamwork in medical practice.

Dr. Armstrong’s dedication to advancing diabetic foot care is evident through his extensive research, including over 600 peer-reviewed articles, and his leadership roles, such as founding the Southwestern Academic Limb Salvage Alliance (SALSA). His work continues to inspire a new generation of clinicians committed to reducing preventable amputations and improving patient quality of life.:contentReference[oaicite:15]{index=15}

Read the full interview on the Diabetic Foot Online website.

Keywords:
David Armstrong,
diabetic foot care,
limb preservation,
SALSA,
Keck School of Medicine

Study Reveals ‘Invisible Wounds’ in Diabetic Foot Ulcers: Rethinking Wound Closure Criteria

A recent study by the National Institutes of Health (NIH) Diabetic Foot Consortium, led by researchers at the University of Pittsburgh, has uncovered that diabetic foot ulcers (DFUs) appearing healed may still possess compromised skin barriers, making them prone to reopening. Published in Diabetes Care, the study suggests that the current FDA definition of wound closure may not adequately reflect true healing. :contentReference[oaicite:4]{index=4}:contentReference[oaicite:5]{index=5}

Key Highlights:

• Functional vs. Visual Healing: The study found that wounds meeting the FDA’s closure criteria—complete skin coverage without discharge for two weeks—might still have defective barrier functions, leading to potential re-injury. :contentReference[oaicite:8]{index=8}
• Transepidermal Water Loss (TEWL) as an Indicator: Researchers utilized a handheld device to measure TEWL, discovering that higher TEWL readings in closed wounds correlated with a greater likelihood of ulcer recurrence. :contentReference[oaicite:11]{index=11}
• Study Findings: Among 368 participants with recently healed DFUs, 22% experienced wound reopening within 16 weeks. Wounds with TEWL values exceeding 30 were approximately 2.7 times more likely to reopen compared to those with lower readings. :contentReference[oaicite:14]{index=14}

These findings highlight the importance of assessing not just the visual appearance of wound closure but also the functional integrity of the skin barrier. Incorporating TEWL measurements into standard wound assessment protocols could enhance the prediction of wound recurrence and inform more effective treatment strategies. :contentReference[oaicite:17]{index=17}:contentReference[oaicite:18]{index=18}

Read the full article on the Medical Xpress website.

Keywords:
diabetic foot ulcers,
wound closure,
TEWL,
Chandan Sen,
Gayle Gordillo,
Sashwati Roy

Advances in Burn Wound Management: Innovative Strategies for Healing and Infection Control

A recent literature review published in Wounds explores the latest developments in burn wound management, emphasizing innovative strategies that enhance healing and infection control. The article provides a comprehensive overview of burn wound causes, classifications, and treatments, discussing the healing phases, potential infections, and complexities associated with conventional treatments. It also highlights advanced techniques that have proven effective in reducing hospital stays and making treatment more cost-effective.

Key Highlights:

• Advanced Therapies: The review discusses the use of adipose tissue-derived stem cells (ADSCs), bone marrow-derived stem cells (BMSCs), and umbilical cord-derived stem cells (UDSCs) in promoting burn wound healing.
• Innovative Materials: The application of acellular fish skin (AFS) and extracellular matrix (ECM) components are highlighted as effective in supporting tissue regeneration and reducing inflammation.
• Modern Techniques: The utilization of negative pressure wound therapy (NPWT) and platelet-derived growth factor (PDGF) are examined for their roles in enhancing wound healing and minimizing infection risks.

These advancements in burn wound management represent significant progress in the field, offering new avenues for treatment that prioritize patient outcomes and cost-effectiveness. By integrating these innovative strategies into clinical practice, healthcare providers can improve healing times, reduce complications, and enhance the overall quality of care for burn patients.

Read the full article on the HMP Global Learning Network website.

Keywords:
burn wound management,
stem cell therapy,
negative pressure wound therapy

NPIAP Hosts 2024 Clinical and Research Symposium in San Diego

The National Pressure Injury Advisory Panel (NPIAP) held its 2024 Clinical and Research Symposium from February 15–16 in San Diego, California. This annual event brought together clinicians, researchers, and industry professionals dedicated to the prevention and treatment of pressure injuries. The symposium served as a hub for sharing the latest science, evidence-based practices, and policy updates in pressure injury care.

Key Highlights:

• Evidence-Based Practice Focus: Sessions highlighted the latest research in pressure injury etiology, staging, and prevention strategies. Emphasis was placed on the integration of new technologies and updated clinical guidelines into practice.
• Multidisciplinary Collaboration: The symposium fostered interdisciplinary dialogue among nurses, physicians, physical therapists, researchers, and product developers. This collaboration helps bridge gaps between clinical innovation and bedside application.
• Policy and Education Updates: Attendees received updates on CMS policies affecting pressure injury documentation and reimbursement, as well as NPIAP’s current initiatives related to public education, guideline dissemination, and global partnerships.

NPIAP’s annual symposium continues to serve as a cornerstone event for professionals working to reduce the prevalence and severity of pressure injuries. With a strong focus on clinical excellence, research translation, and interdisciplinary teamwork, the organization remains a leader in pressure injury education and advocacy.

Learn more about the event and future programming on the NPIAP website.

Keywords:
NPIAP,
pressure injuries,
wound prevention

Alliance of Wound Care Stakeholders Drives Policy Progress in 2024

In a recent blog post on the HMP Global Learning Network, Marcia I. Nusgart, RPh, Executive Director of the Alliance of Wound Care Stakeholders, highlighted the organization’s major regulatory and policy accomplishments throughout 2024. These initiatives have advanced equitable reimbursement, clarified billing practices, and protected patient access to vital wound care treatments.

Key Highlights:

• National Payment Rate for Autologous Blood-Derived Products: The Alliance successfully advocated for CMS to establish a standardized national payment rate under HCPCS code G0465 for platelet-rich plasma (PRP) and similar autologous blood-derived therapies used in chronic wound care. This helps eliminate inconsistent payment practices among Medicare Administrative Contractors (MACs).
• Billing Clarity for Skin Substitutes: The Alliance worked with CMS to clarify that application of skin substitutes in physician office settings can be billed using standard CPT codes, even when the products are provided at no cost. This clarification ensures continued patient access to these critical therapies.
• Revisions to Draft LCDs: The Alliance played a leading role in revising several Local Coverage Determinations (LCDs) involving skin substitutes. Their comments ensured coverage policies remained evidence-based and clinically sound, protecting patient access and aligning guidelines with real-world practice.

Through its active engagement with CMS and MACs, the Alliance of Wound Care Stakeholders continues to shape policy that supports quality care and fair reimbursement. Its ongoing advocacy helps wound care professionals deliver timely, effective treatments while minimizing administrative and financial obstacles.

Read the full article on the HMP Global Learning Network website.

Keywords:
wound care policy,
CMS reimbursement,
skin substitutes,
Marcia Nusgart

Therapeutic Wound and Skin Cleansing: Clinical Evidence and Recommendations

The International Wound Infection Institute (IWII) has released a comprehensive consensus document titled Therapeutic Wound and Skin Cleansing: Clinical Evidence and Recommendations. This publication aims to redefine wound cleansing as a critical, evidence-based component of wound care, moving beyond traditional, ritualistic practices. It emphasizes the importance of targeted cleansing strategies to prevent infection and promote optimal healing outcomes.

Key Highlights:

• Holistic Cleansing Approach: The document underscores the necessity of cleansing not just the wound bed, but also the wound edge, periwound, and surrounding skin. This comprehensive approach ensures the removal of contaminants and supports the overall healing process.
• Evidence-Based Practices: Utilizing a systematic literature review and expert consensus, the guidelines provide clear recommendations on cleansing techniques, solutions, and equipment. This ensures that practices are grounded in the latest clinical evidence.
• Decision-Support Tools: The publication offers practical tools and step-by-step guidance to assist healthcare professionals, caregivers, and patients in performing effective wound cleansing tailored to individual needs.

This consensus document serves as a vital resource for clinicians and caregivers, advocating for the allocation of appropriate time and resources to wound cleansing practices. By adopting these evidence-based recommendations, healthcare providers can enhance patient outcomes, reduce infection rates, and contribute to more efficient wound management strategies.

Read the full consensus document on the Wounds International website.

Keywords:
wound cleansing,
skin cleansing,
IWII,
Terry Swanson,
Emily Haesler,
Karen Ousey

Hypothermically Stored Amniotic Membrane Shows Promise in Diabetic Foot Ulcer Healing

A multicenter retrospective case series published in Wound Care Professional evaluated the effectiveness of hypothermically stored amniotic membrane (HSAM) in the treatment of diabetic foot ulcers (DFUs). Conducted across several U.S. wound care centers, the study followed 50 patients over a 12-week period to assess healing outcomes, wound size reduction, and frequency of treatment applications.

Key Highlights:

• Patient Profile: The average patient age was 66.7 years, with 68% male participants. Most wounds (88%) had been present for less than six months at the time of initial evaluation.
• Wound Area Reduction: Between initial presentation and the first HSAM application, wound area decreased by an average of 68.3%, indicating substantial early progress under standard care alone.
• Wound Closure Outcomes: By week 12, 78% of DFUs had completely closed. The median time to full closure was 55 days, with an average of 5.5 HSAM applications per patient, spaced approximately 7.5 days apart.

These findings suggest that HSAM, when added to standard DFU care, may accelerate wound healing, potentially reducing the risk of complications and lowering long-term treatment costs. The high closure rate within 12 weeks is especially notable in a population with typically slow-to-heal wounds. This study adds to the growing body of evidence supporting the role of biologically active grafts in managing complex diabetic wounds.

Read the full article on the Wound Care Professional website.

Keywords:
HSAM,
diabetic foot ulcers,
wound healing,
Anna Sanchez,
Alan Hartstein,
Hisham Ashry,
Maryam Raza

Global Guideline for Post-Operative Incision Care: A New Standard for Surgical Wound Management

In January 2025, the International Surgical Wound Complications Advisory Panel (ISWCAP) released a groundbreaking global guideline focused exclusively on post-operative incision care. Published as a supplement in the Journal of Wound Care, this consensus document addresses the critical need for standardized practices in managing closed surgical incisions, distinguishing them from chronic wounds and those healing by secondary intention. The guideline serves as a living document, intended to evolve with emerging evidence and clinical insights.

Key Highlights:

• Individualized Treatment Plans: The guideline emphasizes the necessity of tailoring surgical wound treatment plans to individual patient needs, considering factors such as comorbidities, surgical procedure type, and risk of complications.
• Comprehensive Risk Assessment: It provides a framework for assessing risk factors associated with surgical wound complications, including patient-related factors (e.g., diabetes, obesity), surgical factors (e.g., duration of surgery, type of incision), and postoperative care considerations.
• Evidence-Based Dressing Selection: The guideline offers recommendations on selecting appropriate dressings based on wound characteristics, aiming to promote optimal healing environments and reduce the risk of infection.

The ISWCAP’s global guideline represents a significant advancement in postoperative care, providing clinicians with a structured approach to incision management. By focusing on individualized care plans, thorough risk assessment, and evidence-based interventions, the guideline aims to improve patient outcomes, reduce the incidence of surgical wound complications, and standardize care practices across various healthcare settings. As a living document, it will continue to incorporate new research findings and clinical experiences, ensuring its relevance and applicability in the ever-evolving field of surgical wound care.

Read the full guideline on the Journal of Wound Care website.

Keywords:
postoperative incision care,
surgical wound management,
ISWCAP,
Kylie Sandy-Hodgetts,
Sara Carvalhal,
Melissa Rochon,
Gulnaz Tariq

Addressing the Complexities of Chronic Wound Management: Insights from Wound Practice and Research

Chronic wounds represent a significant and growing challenge in healthcare, characterized by their prolonged healing times and the multifaceted factors influencing their progression. In the article “The complexities of managing an ever-growing problem of chronic wounds” by Peta Tehan and Zlatko Kopecki, published in Wound Practice and Research, the authors delve into the intricate nature of chronic wound management and the pressing need for comprehensive strategies to address this issue.

Key Highlights:

• Multifactorial Nature of Chronic Wounds: Chronic wounds often result from a combination of factors, including underlying health conditions, infection, and inadequate wound care practices. The article emphasizes the importance of understanding these contributing elements to develop effective treatment plans.
• Importance of Multidisciplinary Approaches: Effective management of chronic wounds requires collaboration among various healthcare professionals, including physicians, nurses, and specialists. The authors advocate for integrated care models that facilitate communication and coordinated interventions.
• Need for Continued Research and Education: The article highlights gaps in current knowledge and the necessity for ongoing research to inform evidence-based practices. Additionally, it underscores the role of education in equipping healthcare providers with the skills needed to manage complex wound cases effectively.

The complexities inherent in chronic wound management demand a comprehensive and informed approach. By acknowledging the multifaceted nature of these wounds and fostering multidisciplinary collaboration, healthcare systems can enhance patient outcomes and reduce the burden of chronic wounds. Continued research and education are pivotal in advancing wound care practices and addressing this persistent healthcare challenge.

Read the full article on the Journal of Wound Care website.

Keywords:
chronic wounds,
wound management,
multidisciplinary care,
Peta Tehan,
Zlatko Kopecki

Addressing the Complexities of Chronic Wound Management: Insights from Wound Practice and Research

Chronic wounds represent a significant and growing challenge in healthcare, characterized by their prolonged healing times and the multifaceted factors influencing their progression. In the article “The complexities of managing an ever-growing problem of chronic wounds” by Peta Tehan and Zlatko Kopecki, published in Wound Practice and Research, the authors delve into the intricate nature of chronic wound management and the pressing need for comprehensive strategies to address this issue. :contentReference[oaicite:5]{index=5}

Key Highlights:

• Multifactorial Nature of Chronic Wounds: Chronic wounds often result from a combination of factors, including underlying health conditions, infection, and inadequate wound care practices. The article emphasizes the importance of understanding these contributing elements to develop effective treatment plans.
• Importance of Multidisciplinary Approaches: Effective management of chronic wounds requires collaboration among various healthcare professionals, including physicians, nurses, and specialists. The authors advocate for integrated care models that facilitate communication and coordinated interventions.
• Need for Continued Research and Education: The article highlights gaps in current knowledge and the necessity for ongoing research to inform evidence-based practices. Additionally, it underscores the role of education in equipping healthcare providers with the skills needed to manage complex wound cases effectively.

The complexities inherent in chronic wound management demand a comprehensive and informed approach. By acknowledging the multifaceted nature of these wounds and fostering multidisciplinary collaboration, healthcare systems can enhance patient outcomes and reduce the burden of chronic wounds. Continued research and education are pivotal in advancing wound care practices and addressing this persistent healthcare challenge.

Read the full article on the Wound Practice and Research website.

Keywords:
chronic wounds,
wound management,
multidisciplinary care,
Peta Tehan,
Zlatko Kopecki

Integral Debridement in the Postoperative Setting: An Expert’s Perspective

In a recent article published by WoundSource, Dr. Abigail E. Chaffin, MD, FACS, CWSP, MAPWCA, explores the application of integral debridement in postoperative wound care. This advanced approach involves the synergistic use of multiple debridement techniques to optimize wound healing, particularly in complex postoperative wounds. :contentReference[oaicite:5]{index=5}

Key Highlights:

• Comprehensive Debridement Strategy: Integral debridement combines mechanical, chemical, biological, and novel methods to enhance the effectiveness of wound bed preparation. This approach tailors debridement techniques to individual patient needs and clinician expertise. :contentReference[oaicite:10]{index=10}
• Application in Complex Wounds: Postoperative wounds, including those resulting from trauma, surgical dehiscence, and inflammatory conditions, present unique challenges such as residual necrotic tissue and microbial colonization. Integral debridement addresses these issues by employing techniques like sharp excisional debridement, ultrasonic debridement, and negative pressure wound therapy with instillation and dwell (NPWTi-d). :contentReference[oaicite:15]{index=15}
• Adjunctive Therapies: The use of pure hypochlorous acid (pHA) wound irrigation and highly charged fiber dressings (e.g., UrgoClean Ag) extends the benefits of debridement between sessions, aiding in slough removal and microbial management. :contentReference[oaicite:18]{index=18}

Dr. Chaffin reports that incorporating integral debridement into her practice has led to notable improvements in wound healing outcomes, including decreased pain and increased patient comfort. By consistently addressing microbial burden and optimizing wound bed preparation, these advanced strategies enhance healing trajectories for complex wounds. :contentReference[oaicite:23]{index=23}

Read the full article on the WoundSource website.

Keywords:
integral debridement,
postoperative wound care,
Abigail E. Chaffin

Human Keratin Matrix Accelerates Healing of Venous Leg Ulcers: A Case Series

A recent case series published in the Journal of Wound Care explores the efficacy of a novel human keratin matrix (HKM) in conjunction with standard of care (SoC) for treating venous leg ulcers (VLUs). Conducted by Dr. George Koullias and Dr. Allison N. Ramey-Ward, the study assesses the healing outcomes of VLUs treated with HKM alongside indicated vascular interventions and conventional wound care practices.

Key Highlights:

• Significant Reduction in Wound Size: Very large VLUs (>200 cm²) exhibited an average size reduction of 71% within 10 weeks, achieving a 50% reduction within four HKM applications. :contentReference[oaicite:7]{index=7}
• Rapid Healing in Smaller Ulcers: Smaller VLUs (<35 cm²) reduced by 50% in size within the first three weeks of treatment, with 88.9% achieving complete healing after an average of 4.5 HKM applications over 6.5 weeks. :contentReference[oaicite:10]{index=10}
• Enhanced Healing Rates: The integration of HKM with SoC demonstrated accelerated healing compared to SoC alone, suggesting HKM’s potential to improve outcomes in hard-to-heal VLUs.

The study underscores the potential of human keratin matrices as a valuable adjunct in the management of chronic VLUs, offering promising results in both large and small ulcerations. By facilitating faster wound closure, HKM may contribute to improved patient quality of life and reduced healthcare burdens associated with prolonged wound care.

Read the full article on the Journal of Wound Care website.

Keywords:
human keratin matrix,
venous leg ulcers,
wound healing,
George Koullias,
Allison N Ramey-Ward

CuraMedical: Innovating Hemostatic Solutions in Surgical Care

Founded in 1998 and headquartered in Assendelft, Netherlands, CuraMedical B.V. is a privately held medical device company specializing in the development, manufacturing, and marketing of hemostatic agents. With a commitment to quality and innovation, CuraMedical has established itself as a trusted provider of surgical solutions, distributing products to over 50 countries worldwide. :contentReference[oaicite:4]{index=4}

Key Highlights:

• Comprehensive Hemostatic Product Line: CuraMedical offers a range of absorbable and non-absorbable hemostatic products, including CuraSpon®, CuraCel®, CuraTamp®, and CuraWax®. :contentReference[oaicite:7]{index=7}
• Global Reach and Compliance: The company’s products are distributed in over 50 countries, adhering to international standards such as ISO 13485 and the EU Medical Device Directive. :contentReference[oaicite:10]{index=10}
• Commitment to Quality and Innovation: CuraMedical employs leading-edge technology and maintains rigorous quality control processes to ensure reliable product performance. :contentReference[oaicite:13]{index=13}

CuraMedical’s dedication to advancing surgical care through innovative hemostatic solutions underscores its role as a key player in the global medical device industry. By focusing on quality, compliance, and customer satisfaction, the company continues to contribute significantly to improved surgical outcomes and patient care worldwide.

Learn more about the company on the CuraMedical website.

Keywords:
CuraMedical,
hemostatic agents,
surgical care

Collagen-Alginate Dressing Enhances Healing and Quality of Life in Venous Leg Ulcer Patients

An observational study published in Wound Management & Prevention evaluated the efficacy and safety of a native bovine collagen-alginate dressing (Cutimed® Epiona®) in treating non-healing venous leg ulcers (VLUs). Conducted at the Northwell Health System Comprehensive Wound Care Healing Center and Hyperbarics in New York, the study involved 60 patients over a four-week period. The research aimed to assess wound area reduction, pain management, and improvements in wound-related quality of life (QoL).:contentReference[oaicite:7]{index=7}

Key Highlights:

• Significant Wound Area Reduction: The mean wound area decreased from 17.8 ± 11.2 cm² to 11.4 ± 9.0 cm², with four patients achieving complete wound closure within the study period. :contentReference[oaicite:10]{index=10}
• Improved Pain Management: Patients reported decreased wound pain after two weeks of treatment, accompanied by a reduction in analgesic intake. :contentReference[oaicite:13]{index=13}
• Enhanced Quality of Life: Assessments using the Wound-QoL-17 questionnaire indicated significant improvements in patients’ wound-related QoL, correlating with the observed wound area reduction. :contentReference[oaicite:16]{index=16}

The study concluded that the collagen-alginate dressing is a safe and effective adjunct to standard wound care practices, promoting healing and improving patient outcomes in cases of hard-to-heal VLUs. Healthcare professionals rated the dressing’s performance as “very good” or “good,” and patients reported high levels of comfort during use. :contentReference[oaicite:21]{index=21}

Read the full article on the Wound Management & Prevention website.

Keywords:
venous leg ulcer,
collagen-alginate dressing,
wound healing,
Alisha Oropallo,
Amit S. Rao,
Sally Kaplan,
Farisha Baksh,
Christina Del Pin

Improving Patient Outcomes With Integral Debridement

The May 2025 edition of WoundSource’s Practice Accelerator spotlights “Integral Debridement,” an advanced, evidence-based approach to wound bed preparation. This strategy combines multiple debridement modalities—such as sharp, enzymatic, mechanical, and antimicrobial techniques—tailored to the wound’s characteristics, patient comorbidities, and care setting. The goal is to enhance healing outcomes, particularly in complex or chronic wounds.

Key Highlights:

• Multimodal Synergy: Integral debridement leverages a combination of methods—including conservative sharp debridement, hypochlorous acid cleansing, and silver-impregnated dressings—to effectively remove necrotic tissue and biofilm, fostering a conducive environment for healing. :contentReference[oaicite:9]{index=9}
• Continuity Across Care Settings: This approach ensures consistent wound management throughout various care environments, from inpatient to home care, by employing tools like UrgoClean Ag dressings and Vashe® hypochlorous acid soaks that maintain debridement effects between clinical visits.
• Patient-Centered Customization: Integral debridement emphasizes individualized care plans, considering factors such as wound type, patient pain tolerance, and overall health to select the most appropriate combination of debridement techniques.

By adopting integral debridement, clinicians can address the multifaceted barriers to wound healing more effectively, leading to improved patient outcomes, reduced infection rates, and enhanced quality of life for those with complex wounds.

Read the full article on the WoundSource website.

Keywords:
integral debridement,
wound bed preparation,
chronic wound management

Global Leaders Unite in Shijiazhuang to Combat Diabetes and Prevent Amputation

The 11th Shijiazhuang International Diabetes Conference, held on May 16, 2025, at The Second Hospital of Shijiazhuang in China, brought together over 1,000 clinicians, scientists, and policy leaders from around the world. The event focused on urgent challenges and innovative solutions in diabetes care, emphasizing prevention, technology, and limb preservation. :contentReference[oaicite:5]{index=5}

Key Highlights:

• Keynote Address by Prof. David G. Armstrong: Distinguished Professor of Surgery and Neurological Surgery at the University of Southern California and Founding President of the American Limb Preservation Society, Prof. Armstrong delivered a keynote titled “The Diabetic Foot and Wound Healing: Looking Back to Look Forward,” discussing the evolution of global diabetic foot care and future prevention strategies. :contentReference[oaicite:8]{index=8}
• International Collaboration: Speakers from various countries shared insights, including Prof. Marg McGill (Australia) on national foot care models, Prof. Vanessa Nube (Australia) on equitable foot care delivery, Prof. Carlo Fornaini (Italy) on laser therapy in oral health for diabetics, Prof. Dirk Hochlenert (Germany) on chronic disease management programs, and Dr. Peter Lin (Canada) on microplastics’ impact on peripheral artery disease. :contentReference[oaicite:11]{index=11}
• China’s Leadership in Diabetic Research: The conference highlighted China’s advancements in diabetic kidney disease, digital health, biomechanics, stem cell therapies, and comprehensive foot ulcer and vascular care. :contentReference[oaicite:14]{index=14}

This conference underscored the importance of global collaboration in combating diabetes and preventing amputations. By sharing knowledge and strategies, healthcare professionals aim to reduce preventable complications and improve patient outcomes worldwide.

Read the full article on the Diabetic Foot Online website.

Keywords:
diabetes conference,
limb preservation,
global health collaboration

Blisters and Bullous Disease: Infection or Autoimmune?

A recent article in Advances in Skin & Wound Care explores the diagnostic challenges of distinguishing between infectious and autoimmune blistering skin conditions. The piece emphasizes the importance of accurate diagnosis, as treatment strategies differ significantly between bacterial infections like impetigo and autoimmune diseases such as pemphigus vulgaris. :contentReference[oaicite:5]{index=5}

Key Highlights:

• Infectious Blisters: Impetigo, a common superficial bacterial infection, can present with bullous or nonbullous lesions. Bullous impetigo is typically caused by toxin-producing Staphylococcus aureus and manifests as deeper, larger blisters. :contentReference[oaicite:8]{index=8}
• Autoimmune Blisters: Pemphigus vulgaris (PV) is a severe autoimmune blistering disease characterized by fragile, flaccid blisters that often begin in the oral mucosa. Early diagnosis and treatment with high-dose corticosteroids and immunosuppressants are crucial to reduce mortality rates. :contentReference[oaicite:11]{index=11}
• Diagnostic Approach: Differentiating between infectious and autoimmune causes involves clinical assessment, histological examination, and immunofluorescent studies to detect specific autoantibodies. :contentReference[oaicite:14]{index=14}

Understanding the underlying cause of blistering skin conditions is essential for effective management. Clinicians should maintain a high index of suspicion and utilize appropriate diagnostic tools to distinguish between infectious and autoimmune etiologies.

Read the full article on the Advances in Skin & Wound Care website.

Keywords:
blisters,
pemphigus vulgaris,
impetigo

Skin-Sparing Surgery Reduces Costs and Improves Outcomes in Necrotizing Soft Tissue Infections

A recent study published in Wounds evaluates the effectiveness of skin-sparing surgery (SSS) in managing necrotizing soft tissue infections (NSTIs). Conducted at a regional burn and wound center, the research highlights how SSS can lead to better clinical outcomes and lower healthcare costs for patients suffering from these severe infections. :contentReference[oaicite:2]{index=2}

Key Highlights:

• Improved Clinical Outcomes: Patients undergoing SSS experienced reduced mortality rates and shorter hospital stays compared to traditional surgical approaches.
• Cost-Effective Treatment: The SSS approach was associated with decreased healthcare costs, making it a financially viable option for managing NSTIs.
• Preservation of Healthy Tissue: SSS focuses on removing necrotic tissue while preserving viable skin, facilitating better wound healing and potentially reducing the need for complex reconstructive procedures.

This study underscores the potential of skin-sparing surgery as a beneficial strategy in the treatment of necrotizing soft tissue infections, offering both clinical and economic advantages.

Read the full article on the Wounds website.

Keywords:
necrotizing soft tissue infection,
skin-sparing surgery,
wound care costs

Introducing the American College of Clinical Wound Specialists (ACCWS)

The American College of Clinical Wound Specialists (ACCWS) is a multidisciplinary organization dedicated to advancing wound care through education, certification, and professional collaboration. By uniting certified wound care professionals, ACCWS fosters a community committed to delivering evidence-based care and advocating for the recognition of wound care specialists.

Key Highlights:

• Educational Initiatives: ACCWS offers both on-site and conference-based educational programs, with plans to introduce online courses, ensuring accessible, high-quality wound care education for all members.
• Advocacy and Certification: The organization supports professionals holding certifications such as CWS®, CWSP®, and WCC®, promoting their recognition and validity in clinical practice and reimbursement policies.
• Leadership and Governance: The ACCWS Board of Directors comprises esteemed professionals, including Chairwoman Tracy Winkley, MPT, CWS, CLT, FACCWS, DAPWCA; Immediate Past Chair Jean Archer, DPM, FACPM, FACCWS, FASPS, CWS; Chair Elect Lonnie Lassiter, MD, MBA; Treasurer Louis Thibodeaux, MD, FACS; Secretary Emily Greenstein, MD; and Education Chair Kelly McFee, DNP, FNP-C, FACCWS.

Through its commitment to education, certification, and advocacy, ACCWS plays a pivotal role in enhancing the standards of wound care, supporting clinicians in their professional growth, and ultimately improving patient outcomes.

Learn more about the organization on the ACCWS website.

Keywords:
ACCWS,
wound care education,
wound care certification

Contact Dermatitis from Common Wound Care Products May Worsen Chronic Ulcers

A recent study highlighted by HCPLive reveals that contact dermatitis triggered by standard wound care products may significantly impede the healing of chronic ulcers. Conducted at the Wound Healing Institute of Southeast Wisconsin, the study emphasizes the overlooked impact of allergic reactions in patients with non-healing wounds.

Key Highlights:

• Widespread Sensitivities: 15 out of 16 patients with chronic ulcers tested positive for contact dermatitis in patch tests using commonly applied wound care products.
• Delayed Healing: Allergic reactions to these products can worsen chronic ulcers and interfere with effective treatment.
• Diagnostic Implications: The study calls for broader awareness and improved diagnostic testing to identify contact dermatitis in chronic wound care patients.

This research underscores the importance of considering allergic reactions as a complicating factor in chronic ulcer management, urging clinicians to incorporate allergy assessments into routine wound evaluations.

Read the full article on the HCPLive website.

Keywords:
contact dermatitis,
chronic ulcers,
wound care products

Legs Matter: Elevating Awareness for Lower Limb and Foot Health

The Legs Matter campaign is a UK-wide initiative dedicated to raising awareness about lower leg and foot conditions, emphasizing the importance of early diagnosis and effective treatment. Established in 2018, this coalition comprises eight healthcare charities and not-for-profit organizations, including the Society of Tissue Viability, Accelerate, The British Lymphology Society, The Royal College of Podiatry, Foot in Diabetes UK, Leg Ulcer Forum, Lindsay Leg Club Foundation, and the Society of Vascular Nurses [source].

Key Objectives:

• Increase Awareness: Educate the public and healthcare professionals about the significance of leg and foot health.
• Promote Early Intervention: Encourage prompt diagnosis and treatment to prevent complications.
• Provide Resources: Offer evidence-based information and support for patients and clinicians.

Annual Awareness Week: Each year, Legs Matter hosts an Awareness Week to spotlight the importance of leg and foot health. The 2025 event is scheduled for 9–13 June, focusing on the power of speaking up about experiences in lower limb care [source].

Get Involved: Healthcare professionals and community members can participate by accessing free action packs, which include posters, flyers, and patient leaflets to promote the campaign locally [source].

Learn more about the campaign and access resources on the Legs Matter website.

Keywords:
Legs Matter campaign,
Lower limb health awareness,
Society of Tissue Viability,
Legs Matter Awareness Week

Diabetic Foot Ulcer: Charting the Depths With Intact Fish Skin

Join us for an insightful webinar exploring the early management of diabetic foot ulcers (DFUs) using intact fish skin grafts. This session delves into the genesis and application of this innovative treatment, offering a comprehensive overview of its role in wound care.

Webinar Details:

• Date: Tuesday, June 10, 2025
• Time: 12:00 PM EDT
• Presenter: John Lantis, II MD, FACS

Dr. Lantis will share his expertise on the utilization of intact fish skin grafts in managing DFUs, discussing clinical experiences and outcomes. Attendees will gain valuable insights into this emerging therapy and its potential benefits in wound healing.

Register for the webinar on the Podiatry.com website.

Keywords:
Diabetic foot ulcer,
Intact fish skin graft,
John Lantis,
DFU management

AI in Wound Assessment: Transforming Chronic Wound Care

Artificial intelligence (AI) is revolutionizing wound care by transforming how clinicians assess and manage chronic wounds. By automating measurements, enhancing diagnostic precision, and enabling remote monitoring, AI-powered tools address the shortcomings of traditional manual assessments, which are often subjective, time-consuming, and variable. From smartphone-based imaging to deep learning algorithms, AI delivers data-driven insights that improve treatment planning and patient outcomes for conditions like diabetic ulcers, pressure injuries, and venous leg ulcers. This article delves into AI’s impact on wound assessment, offering wound care professionals a glimpse into a technology poised to redefine clinical practice.

The Need for AI in Wound Assessment

Chronic wounds affect over 6 million Americans, costing healthcare systems billions annually. Accurate assessment is crucial to guide treatments, prevent infections, and accelerate healing. Yet, traditional methods—ruler measurements, visual inspections—rely on clinician experience, leading to inconsistencies. AI overcomes these barriers with standardized, objective analysis. Tools like Healthy.io’s Minuteful for Wound use smartphone cameras with calibration markers to capture high-resolution images, instantly measuring wound dimensions and classifying tissue types (granulation, necrotic, epithelialization). Such automation saves time, reduces errors, and allows clinicians to focus on patient care rather than documentation.

Key Highlights:

• Automated Precision: AI systems like eKare’s inSight measure wound size and tissue composition with 94% accuracy, outperforming manual methods. Deep learning models, such as U-Net, segment wound areas precisely, ensuring reliable data for clinical decisions.
• Advanced Diagnostics: AI tools, including Spectral AI’s DeepView SnapShot, predict healing potential and identify infection risks early. These capabilities enable proactive interventions, improving outcomes for complex wounds.
• Telemedicine Integration: AI apps facilitate remote monitoring, allowing patients to upload wound images for real-time clinician review. This enhances access for rural or bedbound patients, reducing hospital visits.
• Future Potential: AI could integrate with wearables and predictive analytics to forecast complications like amputations. Research continues to address challenges like limited datasets and tissue segmentation accuracy.

Clinical and Economic Benefits

AI’s precision in wound assessment drives significant clinical and economic advantages. By detecting subtle changes in wound characteristics—such as early signs of infection or delayed healing—AI supports tailored treatments, from selecting optimal dressings to initiating therapies like negative pressure wound therapy. Early intervention reduces infection rates and hospital readmissions, critical given chronic wounds’ $20–$30 billion annual U.S. cost. AI’s telemedicine capabilities also empower patients, improving adherence and satisfaction. For clinicians, AI tools integrate into workflows, enhancing documentation for reimbursement and freeing time for patient interaction. A 2024 review notes AI’s potential to standardize care across settings, from hospitals to home care.

Challenges to Overcome

Despite its promise, AI in wound assessment faces obstacles. Limited public datasets hinder model training, especially for complex tissues like necrotic areas, which vary in appearance. Regulatory approval, such as FDA clearance, is essential for credibility, but not all apps meet these standards. Clinicians must balance AI insights with clinical judgment to account for patient-specific factors, avoiding over-reliance. The PMC review emphasizes the need for robust clinical validation and diverse datasets to ensure AI tools perform reliably across populations, particularly for underrepresented groups.

The Road Ahead

AI’s future in wound assessment is brimming with possibility. Integration with wearables could enable real-time wound monitoring, while predictive analytics might forecast complications weeks in advance. Imagine smart bandages that alert clinicians to infection risks or AI models that personalize treatment plans based on genetic and environmental factors. As research advances, collaboration between developers, clinicians, and regulators will be key to overcoming current limitations. For wound care professionals, adopting AI tools now means staying at the forefront of innovation, delivering precise, patient-centered care that transforms lives.

AI in wound assessment is more than a technological leap—it’s a new era in chronic wound care. By automating assessments, enhancing diagnostics, and bridging access gaps, AI empowers clinicians to achieve better outcomes. Wound care professionals are urged to explore these tools, stay updated on advancements, and integrate AI into their practice to elevate care standards.

Keywords:
AI wound assessment,
Wound care,
Chronic wounds,
Deep learning,
Telemedicine

Global Summit on Ostomy Care: Optimizing Outcomes with Convexity

The Global Innovation Summit Series hosts a free, accredited webinar on optimizing ostomy care through clinical assessment and convexity selection. This event equips wound care professionals with evidence-based strategies for better patient outcomes.

Key Highlights:

• Clinical Assessment: Learn to evaluate peristomal skin and stoma to select optimal convex barriers.
• Convexity Selection: Explore evidence-based approaches to match convexity characteristics to patient needs.
• Interactive Learning: Engage in case studies and Q&A with leading ostomy care experts.
• Practical Skills: Gain techniques to reduce complications like leaks and skin issues.

This summit offers wound care professionals actionable insights to enhance ostomy management.

Register for the event at the Global Innovation Summit Series.

Keywords:
Ostomy care,
Convexity,
Peristomal skin,
Wound care,
Clinical assessment

OxyGenesys Dissolved Oxygen Dressing: Clinical Trial Insights

A ClinicalTrials.gov study tested the OxyGenesys Dissolved Oxygen Dressing in abdominoplasty patients to assess its wound healing potential. While inconclusive, the trial offers valuable insights into oxygen therapy for wound care professionals.

Key Highlights:

• Study Design: Patients received OxyGenesys on one side and Tegaderm on the other, serving as their own controls.
• Findings: No significant healing benefits were observed, with data collection incomplete due to inconclusive results.
• Oxygen Therapy: OxyGenesys aimed to enhance chronic wound recovery through continuous oxygen delivery.
• Clinical Relevance: The trial highlights challenges in validating oxygen-based wound treatments, guiding future research.

This study informs clinicians’ approach to oxygen therapy in wound care innovation.

Learn more about the trial on the ClinicalTrials.gov study page.

Keywords:
Oxygen therapy,
OxyGenesys,
Wound healing,
Topical oxygen,
Chronic wounds

MolecuLightDX: Revolutionizing Wound Care with Fluorescence Imaging

A new MolecuLight video demonstrates the MolecuLightDX, an FDA-cleared device using fluorescence imaging to detect bacteria in wounds, enhancing clinical outcomes. It supports real-time assessment and targeted treatment for wound care professionals.

Key Highlights:

• Bacterial Detection: Visualizes bacteria at or below the skin surface, aiding precise wound assessment.
• FDA-Cleared: Clinically validated for reliability in detecting bacterial presence in various wound types.
• Clinical Applications: Guides debridement and treatment, reducing infection risks and improving healing.
• User-Friendly: Portable, non-invasive, and integrates seamlessly into clinical workflows.

The MolecuLightDX empowers clinicians to optimize wound management with cutting-edge technology.

Learn more about the product on the MolecuLightDX product sheet.

Keywords:
Fluorescence imaging,
MolecuLightDX,
Wound assessment,
Bacterial detection,
Wound care technology

Dr. Lisa Gould: Blending Classical Guitar with Wound Care Expertise

A recent Wound Healing Society feature highlights Dr. Lisa Gould, a plastic surgeon who combines her wound care expertise with classical guitar performance. Practicing at South Shore Hospital, she brings discipline from music to clinical precision.

Key Highlights:

• Wound Care Leadership: Dr. Gould, a Wound Healing Society leader, advances research and treatment for complex wounds.
• Classical Guitar: She performs at events like the Rhode Island Philharmonic’s Amica Rush Hour Series.
• Clinical Role: As a plastic surgeon at South Shore Hospital, she specializes in difficult wound problems.
• Multidisciplinary Approach: Her musical discipline enhances focus and empathy in patient care.

Dr. Gould’s unique blend of music and medicine inspires wound care professionals to embrace diverse passions.

Read the full article on the Caroline Fife, MD website.

Keywords:
Wound care expert,
Classical guitar,
Plastic surgery,
Wound Healing Society,
Lisa Gould

St. Louis Wound & Vascular Symposium 2025

The St. Louis Wound & Vascular Symposium, set for June 21, 2025, at the Hilton St. Louis Frontenac, offers wound care professionals 7 CME hours. This one-day event features expert-led sessions on vascular surgery, complex wound management, and innovative treatments.

Key Highlights:

• CME Credits: Earn 7 CME hours through advanced wound and vascular care sessions.
• Expert Topics: Explore vascular surgery, complex cases, and new treatments with leading specialists.
• Audience: Designed for clinicians, nurses, and specialists in vascular surgery, dermatology, podiatry, and plastic surgery.
• Networking: Connect with peers to enhance clinical practice and share insights.

This symposium is an essential opportunity for wound care professionals to advance their expertise.

Register for the event on the St. Louis Wound & Vascular Symposium website.

Keywords:
Wound care symposium,
CME event,
Vascular surgery,
Complex wound management,
St. Louis symposium

Comparative Assessment of Negative Pressure Wound Therapy Systems

A recent study in the Journal of Wound, Ostomy and Continence Nursing compares various Negative Pressure Wound Therapy (NPWT) systems, evaluating their efficacy, usability, and patient outcomes. The research provides insights to guide clinicians in selecting optimal NPWT devices for wound management.

Key Highlights:

• Efficacy Comparison: The study assesses NPWT systems based on healing rates, infection control, and exudate management across different wound types.
• Usability Factors: Device portability, ease of application, and patient comfort are critical in determining clinical suitability.
• Patient Outcomes: Systems with advanced features, like adjustable pressure settings, showed improved patient satisfaction and faster healing.
• Clinical Recommendations: The findings advocate for tailored NPWT selection based on wound characteristics and patient needs.

This research is a valuable resource for wound care professionals seeking to optimize NPWT use in clinical practice.

Read the full article on the Journal of Wound, Ostomy and Continence Nursing website.

Keywords:
Negative pressure wound therapy,
NPWT systems,
Wound healing,
Patient outcomes,
Sarah Johnston

Advanced Wound Care Summit USA 2025: Uniting Industry Leaders

The Advanced Wound Care Summit USA, scheduled for July 15-16, 2025, in Boston, is a premier industry-led forum bringing together wound care experts to drive innovation and collaboration. This event focuses on strategic partnerships, cutting-edge research, and overcoming key challenges in wound care product development.

Key Highlights:

• Innovative Solutions: Explore novel clinical trial designs and next-generation diagnostic tools to advance wound care technologies.
• Reimbursement Challenges: Address barriers to skin substitute product adoption through improved reimbursement models.
• Networking Opportunities: Connect with C-level executives, R&D directors, and investors to foster partnerships and growth.
• Expert Insights: Hear from leading figures like Dr. Thomas Serena and Dr. David G. Armstrong on biomaterials, personalized medicine, and regulatory strategies.

This summit is a must-attend for wound care professionals seeking to shape the future of patient care through innovation and collaboration.

Learn more and register at the Advanced Wound Care Summit USA website.

Keywords:
Wound care innovation,
Clinical trials,
Reimbursement models,
Personalized medicine,
Thomas Serena,
David G. Armstrong

Venous Leg Ulcers: Healing Rates and Time to Closure

A recent study in the Advances in Skin & Wound Care journal examines healing rates and time to closure for venous leg ulcers (VLUs), providing insights into effective treatment strategies. The research highlights factors influencing healing outcomes and optimal management approaches.

Key Highlights:

• Healing Rate Factors: Compression therapy and wound bed preparation significantly improve healing rates for VLUs.
• Time to Closure: The study identifies patient-specific factors, such as comorbidities and adherence, that affect the duration of VLU healing.
• Treatment Protocols: Standardized protocols, including advanced dressings and regular monitoring, are critical for faster closure.
• Clinical Implications: The findings support tailored interventions to enhance outcomes and reduce recurrence in VLU management.

This study offers valuable guidance for clinicians aiming to optimize venous leg ulcer treatment and improve patient quality of life.

Read the full article on the Advances in Skin & Wound Care website.

Keywords:
Venous leg ulcers,
Healing rates,
Compression therapy,
Wound management,
Laura Bolton

Common Missteps in Wound Care: Insights for Better Practice

In a recent blog post, Caroline Fife, MD, critiques common mistakes in wound care, highlighting practices that hinder effective treatment. Drawing from her expertise, the article emphasizes evidence-based approaches to improve patient outcomes and avoid outdated or ineffective methods.

Key Highlights:

• Avoiding Outdated Treatments: The post debunks reliance on non-evidence-based practices, such as inappropriate dressing choices, that can delay healing.
• Proper Wound Assessment: Accurate diagnosis of wound type and underlying causes is critical to selecting effective treatments.
• Patient Education: Educating patients on wound care protocols enhances compliance and supports better healing outcomes.
• Evidence-Based Focus: Clinicians are urged to stay updated on research to avoid common pitfalls and adopt best practices.

This article is a valuable resource for wound care professionals seeking to refine their approach and improve patient care.

Read the full article on Caroline Fife, MD’s website.

Keywords:
Wound care mistakes,
Evidence-based practice,
Wound assessment,
Patient education,
Caroline Fife

Reframing Diabetes Treatment: A Shift Toward Prevention

A recent article from Podiatry Today advocates for a proactive approach to diabetes management, emphasizing prevention over reactive treatment. By focusing on early intervention and lifestyle changes, healthcare providers can reduce complications, including diabetic foot ulcers, and improve patient outcomes.

Key Highlights:

• Preventive Focus: Early education and lifestyle modifications, such as diet and exercise, are critical to preventing diabetes progression and related complications.
• Foot Health Emphasis: Regular podiatric assessments can identify risks early, reducing the incidence of ulcers and amputations in diabetic patients.
• Patient Empowerment: Encouraging patient engagement through education and self-care practices fosters better long-term health outcomes.
• Interdisciplinary Approach: Collaboration between podiatrists, endocrinologists, and primary care providers is essential for comprehensive diabetes prevention strategies.

This perspective shift offers clinicians actionable insights to prioritize prevention in diabetes care, particularly for foot-related complications.

Read the full article on the HMP Global Learning Network website.

Keywords:
Diabetes prevention,
Diabetic foot ulcers,
Podiatric care,
Patient education,
Preventive healthcare,
Robert G. Smith

Negative Pressure Wound Therapy with Instillation: Enhancing Wound Healing

A recent study in the Journal of Wound, Ostomy and Continence Nursing explores the efficacy of Negative Pressure Wound Therapy with Instillation (NPWTi), highlighting its role in improving wound healing outcomes. The research emphasizes the combination of negative pressure and periodic instillation of solutions to manage complex wounds effectively.

Key Highlights:

• Enhanced Wound Cleaning: NPWTi delivers cleansing solutions to the wound bed, reducing bioburden and promoting a cleaner healing environment.
• Improved Healing Rates: The study reports faster wound closure and reduced infection rates compared to standard NPWT in specific wound types.
• Clinical Applications: NPWTi is particularly beneficial for chronic, infected, or high-exudate wounds, offering a targeted approach to complex cases.
• Evidence-Based Practice: The findings support integrating NPWTi into wound care protocols, with recommendations for tailored solution selection and treatment schedules.

This study provides valuable insights for clinicians seeking advanced wound management techniques to optimize patient outcomes.

Read the full article on the Journal of Wound, Ostomy and Continence Nursing website.

Keywords:
Negative pressure wound therapy,
NPWTi,
Wound healing,
Chronic wounds,
Infection management

Palliative Wound Care: Managing Symptoms to Enhance Quality of Life

The European Wound Management Association (EWMA) has published comprehensive guidelines focusing on the management of wound-related symptoms in palliative care settings. Recognizing that not all wounds are healable, the document emphasizes a patient-centered approach aimed at alleviating distressing symptoms and improving the quality of life for individuals with life-limiting conditions.

Key Highlights:

• Symptom Management Focus: The guidelines prioritize the control of pain, odor, exudate, bleeding, and itching over wound healing, acknowledging the unique challenges in palliative wound care.
• Holistic Care Approach: Emphasis is placed on interdisciplinary collaboration, involving dietitians, psychologists, social workers, and palliative care specialists to address the complex needs of patients.
• Patient and Family Involvement: Care plans are encouraged to be developed in partnership with patients and their families, ensuring that treatment aligns with their preferences and goals.
• Education and Research: The document advocates for the inclusion of palliative wound care principles in medical curricula and calls for further research to develop and validate new symptom management interventions.

These recommendations serve as a valuable resource for healthcare professionals, educators, policymakers, and industry stakeholders committed to enhancing palliative wound care practices.

Read the full article on the Journal of Wound Management website.

Keywords:
Palliative wound care,
Symptom management,
Quality of life,
EWMA,
Interdisciplinary care

Stepping Up: A Pharmacist’s Role in Managing Diabetes and Foot Ulcers

The South African Pharmaceutical Journal highlights the critical role pharmacists play in the management of diabetes and associated complications, such as foot ulcers. The article emphasizes the importance of pharmacists in early detection, patient education, and interdisciplinary collaboration to prevent and manage diabetic foot ulcers (DFUs).

Key Highlights:

• Early Detection: Pharmacists are often the first point of contact and can identify early signs of foot complications, facilitating prompt referrals.
• Patient Education: Through counseling, pharmacists can educate patients on foot care practices, glycemic control, and the importance of regular check-ups.
• Interdisciplinary Collaboration: Working alongside healthcare providers, pharmacists contribute to comprehensive care plans, ensuring optimal patient outcomes.
• Medication Management: Pharmacists play a pivotal role in managing medications, monitoring for side effects, and ensuring adherence to treatment regimens.

The article underscores the evolving role of pharmacists from traditional dispensers to integral members of the healthcare team, particularly in chronic disease management and complication prevention.

Read the full article on the South African Pharmaceutical Journal website.

Keywords:
Pharmacist role in diabetes,
Diabetic foot ulcers,
Patient education in diabetes,
Interdisciplinary care

Telemedicine for Wound Management: Enhancing Care Through Remote Monitoring

In the article “Telemedicine for Wound Management,” published in the International Journal of Lower Extremity Wounds, the authors explore the integration of telemedicine into wound care practices. The study highlights how remote monitoring and consultations can improve patient outcomes, especially for those in underserved or remote areas.

Key Highlights:

• Improved Access to Care: Telemedicine bridges the gap for patients who have limited access to specialized wound care facilities, ensuring timely interventions.
• Cost-Effectiveness: Remote consultations can reduce the need for frequent in-person visits, leading to cost savings for both healthcare systems and patients.
• Enhanced Patient Engagement: Patients become more involved in their care through regular virtual check-ins, leading to better adherence to treatment plans.
• Clinical Outcomes: The study notes comparable healing rates between telemedicine-managed wounds and those managed through traditional in-person care.

The authors conclude that telemedicine is a viable adjunct to traditional wound care, offering a flexible and effective approach to managing chronic wounds.

Read the full article on the PubMed Central website.

Keywords:
Telemedicine wound care,
Remote patient monitoring,
Chronic wound management,
Digital health in wound care

Alice Ball: The Trailblazing Chemist Behind a Breakthrough Leprosy Treatment

In the early 20th century, Alice Augusta Ball, a pioneering African American chemist, developed a groundbreaking treatment for leprosy (Hansen’s disease) that significantly improved patient outcomes. Her innovative work involved creating an injectable, water-soluble form of chaulmoogra oil, which had previously been used with limited success due to its poor absorption. Ball’s method, later known as the “Ball Method,” became the most effective treatment for leprosy until the development of sulfonamide drugs in the 1940s.

Despite her monumental contribution, Ball’s achievements were initially overshadowed. After her untimely death at the age of 24, her colleague, Arthur L. Dean, continued her work and published findings without crediting her, leading to the method being erroneously named after him. It wasn’t until years later that Ball’s role was rightfully acknowledged, thanks in part to the efforts of scholars and historians who brought her story to light.

Ball’s legacy has since been honored in various ways, including the declaration of Alice Augusta Ball Day in Hawaii and the installation of a sculpture at the University of Hawaiʻi. Her story serves as a powerful reminder of the importance of recognizing the contributions of all scientists, regardless of gender or race.

Read the full article on the Wound Care Advisor website.

Keywords:
Alice Augusta Ball,
Leprosy treatment history,
Chaulmoogra oil,
Ball Method,
Women in science,
African American scientists

Macrophage-Derived Extracellular Vesicles: A Novel Therapeutic Alternative for Diabetic Wound Healing

A recent study published in the International Journal of Nanomedicine explores the potential of macrophage-derived extracellular vesicles (MDEVs) as a therapeutic approach for diabetic wound healing. The research highlights how MDEVs, as natural nanocarriers, can modulate inflammation and promote tissue regeneration, offering a promising alternative to traditional cell-based therapies.

Key Highlights:

• Immunomodulatory Effects: MDEVs can influence macrophage polarization, shifting the balance towards anti-inflammatory phenotypes, which is crucial in chronic wound environments.
• Enhanced Angiogenesis: The vesicles carry bioactive molecules that stimulate new blood vessel formation, aiding in tissue repair.
• Reduced Fibrosis: By modulating the wound healing process, MDEVs help in minimizing scar tissue formation.
• Safety and Efficacy: As acellular therapies, MDEVs reduce risks associated with cell-based treatments, such as immune rejection and tumorigenicity.

The study suggests that MDEVs could be integrated into existing wound care protocols, potentially improving outcomes for patients with diabetic ulcers.

Read the full article on the Dove Medical Press website.

Keywords:
Macrophage-derived extracellular vesicles,
Diabetic wound healing,
Nanomedicine,
Immunomodulation,
Angiogenesis

Optimizing Diabetic Foot Ulcer Care: Four Steps to Save Limbs Worldwide

Keck Medicine of USC outlines a comprehensive, four-step approach to diabetic foot ulcer (DFU) management, aiming to reduce the global incidence of lower-limb amputations. This strategy emphasizes early detection, interdisciplinary care, and patient empowerment to enhance outcomes for individuals with diabetes.

1. Establishing a “Hot Foot Line”: A dedicated hotline facilitates rapid triage of patients presenting with diabetic foot infections or ischemia, ensuring immediate assessment by a specialized limb-salvage team. This prompt intervention can significantly decrease the risk of major amputations.

2. Developing Wound-Healing Clinics: Specialized outpatient clinics focus on active tissue loss, employing advanced modalities such as total contact casting, vascular diagnostics, and surgical debridement. These clinics aim to expedite healing and reduce hospitalization rates.

3. Establishing Remission Clinics: Post-healing, remission clinics work to prevent ulcer recurrence through patient education, biomechanical evaluations, and preventive interventions. Tools like pressure-relieving footwear and thermal monitoring devices are utilized to maintain ulcer-free periods.

4. Implementing Screening Clinics: Annual foot screenings assess risk factors like neuropathy and peripheral artery disease. Early identification allows for timely referrals to appropriate care pathways, including remission or wound-healing clinics, thereby preventing the progression to limb-threatening conditions.

This model has demonstrated success at Keck Medicine of USC and is adaptable to various healthcare settings globally. By integrating these steps, healthcare systems can proactively manage chronic conditions, ultimately saving limbs and improving quality of life for patients with diabetes.

Read the full article on the Keck Medicine of USC website.

Keywords:
Diabetic foot ulcers,
Foot ulcer care,
Limb salvage,
Amputation prevention,
Keck Medicine of USC,
David G. Armstrong

Sole Purpose 59: Canceled Plans, New Purpose – A Journey to Podiatry School

In the latest installment of the Sole Purpose series, Dr. Santiago shares her inspiring journey to podiatry school, detailing how unexpected life changes led her to discover a new calling in podiatric medicine. Originally set on a different career path, unforeseen circumstances prompted her to reevaluate her goals and ultimately find purpose in helping others through foot and ankle care.

Dr. Santiago candidly discusses the challenges she faced, including the cancellation of her initial plans, and how these obstacles became opportunities for growth and redirection. She emphasizes the importance of resilience and adaptability, qualities that not only guided her through personal transitions but also serve her well in the demanding field of podiatry.

Included in the article is the personal statement she submitted with her podiatry school application, offering readers a glimpse into the motivations and experiences that shaped her decision to pursue this profession. Her story serves as a testament to the idea that setbacks can lead to new beginnings, and that finding one’s true purpose often involves embracing change.

Read the full article on the Podiatry.com website.

Keywords:
Dr. Santiago,
Sole Purpose series,
Journey to podiatry school,
Career change to podiatry,
Personal statement for podiatry school

FDA Clears NEXA™ NPWT System for Home Use — A Major Advancement in Portable Wound Therapy

Advanced Oxygen Therapy Inc. (AOTI) has announced that its NEXA™ Negative Pressure Wound Therapy (NPWT) system has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for use in the home care setting. This expanded indication allows patients to receive the same advanced level of wound care outside of institutional environments, a breakthrough that could improve healing rates and reduce hospital readmissions for chronic and acute wounds.

The clearance (K241515), issued in August 2024, followed rigorous evaluation including a human factors study that confirmed the system’s safety and effectiveness when used by patients or caregivers at home. NEXA is now FDA-cleared for use across acute, extended, and home care environments, aligning with its previous CE Mark approval and international adoption.

“Bringing advanced wound care into the home is the future of healing,” said Dr. Mike Griffiths, CEO of AOTI. “With NEXA, we’re combining the ease and affordability of disposable NPWT with the performance and reliability clinicians expect from traditional systems.”

Key features of the NEXA™ NPWT System:

• Portable and discreet: Lightweight design with a convenient shoulder bag and quiet operation for patient comfort and mobility.
• Extended use: Each unit can be used for up to 56 days, with a rechargeable battery and replaceable dressing kits.
• Innovative fluid management: 120ml pouch-style canister and hydrodynamic pump that functions even with minor leaks.
• Visual-only alerts: Eliminates disruptive audio alarms while maintaining safety.
• Cost-effective care: Low daily cost and reduced need for frequent dressing changes may help healthcare systems save significantly.

Designed to support the healing of a wide range of wound types — including diabetic foot ulcers, venous leg ulcers, pressure injuries, and surgical wounds — NEXA aims to bring hospital-grade therapy to the patient’s doorstep.

Read the full press release on the AOTI website.

Keywords:
NEXA NPWT,
Negative Pressure Wound Therapy,
AOTI,
FDA 510(k) clearance,
Home wound care,
Portable NPWT,
Chronic wound healing

Platelet-Rich Plasma Exosomes: A Novel Approach to Diabetic Foot Ulcer Healing

Diabetic foot ulcers (DFUs) are a significant complication of diabetes, often leading to prolonged healing times and increased risk of infection. Recent research has explored innovative therapies to enhance the healing process. One such study investigates the role of platelet-rich plasma-derived exosomes (PRP-Exos) in promoting wound healing through macrophage polarization.

Understanding PRP-Exos and Macrophage Polarization

Platelet-rich plasma (PRP) is known for its regenerative properties, containing growth factors that aid tissue repair. Exosomes derived from PRP (PRP-Exos) are nano-sized vesicles that carry proteins and genetic material, influencing cell behavior. Macrophages, a type of immune cell, play a pivotal role in wound healing. They exist in two primary phenotypes:

• M1 Macrophages: Pro-inflammatory, involved in initial defense mechanisms.
• M2 Macrophages: Anti-inflammatory, promoting tissue repair and regeneration.

The transition from M1 to M2 macrophages is crucial for effective wound healing. The study by He et al. examines how PRP-Exos influence this polarization, thereby accelerating the healing of DFUs.

Key Findings

• Enhanced Healing: Application of PRP-Exos to diabetic wounds in mice resulted in faster wound closure compared to controls.
• Macrophage Polarization: PRP-Exos promoted the shift of macrophages from the M1 to the M2 phenotype, reducing inflammation and supporting tissue regeneration.
• Collagen Deposition: Treated wounds showed increased collagen deposition, indicating improved structural integrity of the healing tissue.

Clinical Implications

The findings suggest that PRP-Exos could be a promising therapeutic avenue for enhancing DFU healing. By modulating the immune response and promoting tissue repair mechanisms, PRP-Exos offer a targeted approach to address the challenges associated with chronic diabetic wounds.

Read the full article here.

Adapted from: “Platelet-rich plasma-derived exosomes accelerate the healing of diabetic foot ulcers by promoting macrophage polarization toward the M2 phenotype” by Ling He et al., published in Clinical and Experimental Medicine, May 2025. Available under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Holistic Approaches to Diabetic Foot Ulcer Management: Integrating Physical, Physiological, and Psychological Care

In a recent publication in Clinical, Cosmetic and Investigational Dermatology, researchers Prashanth Vas and Nachiappan Chockalingam emphasize the necessity of a comprehensive approach to managing diabetic foot ulcers (DFUs). Their study highlights the intertwined nature of physical, physiological, and psychological factors in patient outcomes.

Key Insights:

• Physical Health: Effective wound care and offloading techniques are crucial for ulcer healing and preventing complications.
• Physiological Factors: Proper glycemic control and vascular health play significant roles in the healing process.
• Psychological Well-being: Addressing mental health aspects, such as depression and anxiety, can improve patient adherence to treatment and overall quality of life.

The authors advocate for integrated care models that encompass these three dimensions, aiming to enhance healing rates and reduce the risk of amputation.

Read the full article on the Diabetic Foot Online website.

Keywords:
Diabetic foot ulcers,
Holistic care,
Psychological well-being,
Prashanth Vas,
Nachiappan Chockalingam

US Wound Registry Releases White Paper on Evaluating Real-World Data in Wound Care

The U.S. Wound Registry (USWR) has published a comprehensive white paper titled “Analysis of Bias Criteria Checklist for Wound Care Registries & EHRs,” aimed at improving the quality and reliability of wound care research derived from real-world data. This document offers a practical tool for identifying bias in observational studies using electronic health records (EHRs), a crucial step in refining clinical decision-making and treatment evaluation.

Key Highlights:

• Wound Care Burden: Chronic wounds affect 8.2 million Medicare patients and cost the healthcare system an estimated $96.8 billion annually.
• Real-World Evidence Gap: Many patients with multiple comorbidities are excluded from randomized controlled trials, making real-world data vital to understanding actual treatment outcomes.
• The ABC Checklist: The Analysis of Bias Criteria (ABC) checklist—modeled after the STROBE Statement—offers a structured approach for assessing observational wound care studies derived from EHRs.
• USWR’s Role: Founded in 2005, USWR is a CMS-approved Qualified Clinical Data Registry (QCDR), focused on measuring, reporting, and improving quality of care in wound and podiatric medicine.

The white paper is especially timely as CMS increasingly emphasizes quality measures and value-based care in wound management. It provides clinicians, researchers, and policymakers with a framework to critically appraise registry-based data in ways that align with both scientific rigor and practical application.

Read the full white paper on the US Wound Registry website.

Keywords:
US Wound Registry,
EHR data,
Bias criteria checklist,
Real-world evidence,
Chronic wounds,
QCDR,
STROBE Statement

Clinical Trial Spotlight: Evaluating RGN-137 for Diabetic Foot Ulcers

Study Title: A Study to Evaluate the Safety and Efficacy of RGN-137 in Subjects With Diabetic Foot Ulcers (DFUs)

ClinicalTrials.gov Identifier: NCT05099367

Study Overview: This Phase 2, randomized, double-blind, placebo-controlled trial aims to assess the safety and efficacy of RGN-137, a topical gel formulation of thymosin beta 4, in promoting the healing of diabetic foot ulcers.

Key Details:

• Intervention: Participants will receive either RGN-137 topical gel or a placebo, applied to the ulcer site.
• Primary Outcome Measure: Proportion of subjects achieving complete ulcer closure within a specified timeframe.
• Secondary Outcome Measures: Time to complete ulcer closure, incidence of ulcer recurrence, and assessment of safety and tolerability.

Eligibility Criteria:

• Adults aged 18 years and older with Type 2 Diabetes Mellitus.
• Presence of a diabetic foot ulcer of a specified size and duration.
• Exclusion of ulcers with active infection or exposure of bone, tendon, or joint capsule.

Study Status: As of the latest update, the trial is actively recruiting participants across multiple sites in the United States.

For more information or to participate, please visit the ClinicalTrials.gov page.

Keywords:
RGN-137,
Thymosin beta 4,
Diabetic foot ulcers,
Clinical trial,
Topical therapy

Reevaluating the ‘Golden Period’ in Traumatic Laceration Repair

Traditionally, the “golden period” for primary closure of traumatic lacerations has been considered to be within 6 to 8 hours post-injury, based on early 20th-century animal studies. However, recent insights suggest that this timeframe may be more flexible than previously thought.

Key Insights:

• Extended Closure Window: Emerging evidence indicates that clean lacerations, especially on the face, may be safely closed up to 24 hours after injury in healthy individuals.
• Factors Influencing Closure Decisions: The decision to close a wound beyond the traditional window should consider the wound’s cleanliness, location, and the patient’s overall health status.
• Individualized Assessment: Rather than adhering strictly to a fixed timeframe, clinicians are encouraged to assess each wound individually, balancing the risks of infection against the benefits of primary closure.

This evolving perspective underscores the importance of personalized clinical judgment in wound management, moving beyond rigid time constraints to optimize patient outcomes.

Read the full article on the Clinical Advisor website.

Keywords:
Traumatic lacerations,
Golden period,
Wound closure timing,
Infection risk,
Clinical judgment

FDA Approves dermaPACE® Shock Wave Device for Diabetic Foot Ulcers

On December 28, 2017, the U.S. Food and Drug Administration (FDA) approved the marketing of the dermaPACE® System, developed by Sanuwave Health, Inc., marking it as the first shock wave device authorized for treating diabetic foot ulcers (DFUs) in the United States. This non-invasive, extracorporeal shock wave therapy (ESWT) device delivers acoustic energy pulses to mechanically stimulate chronic wounds, promoting healing in conjunction with standard diabetic ulcer care.

Key Details:

• Indication: Treatment of chronic, full-thickness diabetic foot ulcers extending through the epidermis, dermis, tendon, or capsule, without bone exposure, and with wound areas ≤16 cm².
• Patient Criteria: Adults aged 22 years and older with DFUs persisting for more than 30 days.
• Clinical Evidence: Approval was based on two multicenter, randomized, double-blind studies involving 336 patients. Results showed a 44% wound closure rate at 24 weeks for patients treated with dermaPACE®, compared to 30% in the control group receiving sham therapy.
• Regulatory Pathway: The device was reviewed under the FDA’s de novo premarket review pathway, establishing a new regulatory classification for similar devices.

Read the full article on the Wound Care Advisor website.

Keywords:
dermaPACE,
Shock wave therapy,
Diabetic foot ulcers,
Sanuwave Health,
FDA approval

Mesenchymal Stem Cell-Derived Exosomes: A Promising Therapeutic Avenue for Diabetic Foot Ulcers

Recent research highlights the potential of mesenchymal stem cell (MSC)-derived exosomes as a novel treatment for diabetic foot ulcers (DFUs). These nano-sized vesicles, secreted by MSCs, are rich in bioactive molecules that can modulate various aspects of the wound healing process.

Key Mechanisms:

• Anti-inflammatory Effects: MSC-derived exosomes can reduce inflammation by modulating immune cell responses, thereby creating a conducive environment for healing.
• Promotion of Angiogenesis: They stimulate the formation of new blood vessels, ensuring adequate oxygen and nutrient supply to the wound site.
• Enhancement of Cell Proliferation and Migration: Exosomes encourage the proliferation and migration of skin cells, essential for tissue regeneration.
• Extracellular Matrix Remodeling: They aid in the remodeling of the extracellular matrix, providing structural support for new tissue formation.

These multifaceted actions position MSC-derived exosomes as a promising cell-free therapeutic strategy for DFUs, potentially overcoming limitations associated with direct stem cell therapies.

Read the full article on the Dove Medical Press website.

Keywords:
Mesenchymal stem cells,
Exosomes,
Diabetic foot ulcers,
Regenerative medicine,
Cell-free therapy

Insulin and Metformin Synergy May Accelerate Diabetic Foot Ulcer Healing

Researchers from Michigan State University and South Shore Hospital have uncovered a potential synergistic effect between two common diabetes medications—insulin and metformin—that may enhance the healing of diabetic foot ulcers (DFUs). Their study, published in ACS Pharmacology and Translational Science, analyzed wound exudate from patients with DFUs and discovered the presence of metformin in the wound fluid of those taking the drug orally. Notably, patients concurrently using insulin injections exhibited significantly higher levels of metformin at the wound site.

Key Findings:

• Metformin was detected in the wound exudate of patients taking the drug orally.
• Patients using both insulin and metformin had increased concentrations of metformin at the wound site.
• This interaction suggests a previously unrecognized synergy between insulin and metformin in promoting wound healing.

These findings could have immediate implications for clinicians treating chronic wounds and for developers of advanced wound dressings. The study was funded by the National Institute of Diabetes and Digestive and Kidney Diseases.

Read the full article on the EurekAlert! website.

Keywords:
Diabetic foot ulcers,
Insulin,
Metformin,
Wound healing,
Morteza Mahmoudi,
Lisa Gould

How Effective Is Bromelain-based Debridement (BBD) in Diabetic Foot Ulcers?

At the Symposium on Advanced Wound Care (SAWC) Spring, a poster presented by Brian McCurdy highlighted the potential benefits of bromelain-based debridement (BBD) for diabetic foot ulcers (DFUs). The post-hoc analysis involved 19 patients, with 12 receiving BBD 5% and 7 receiving a gel vehicle control. Treatments were administered daily for up to 10 sessions over two weeks, followed by weekly assessments for 12 weeks.

Key Findings:

• Complete Debridement: Achieved in 58% of BBD patients compared to 14% in the control group within the two-week treatment period.
• Granulation Tissue Formation: ≥75% granulation observed in a higher proportion of BBD-treated wounds, indicating enhanced wound bed preparation.
• Wound Closure: Defined as complete epithelialization without drainage or dressing use for two weeks, was more frequently attained in the BBD group.

While the subgroup analysis was not powered to detect statistically significant differences, the results suggest that BBD may offer advantages over traditional gel vehicle debridement in promoting wound healing in DFUs.

Read the full article on the HMP Global Learning Network website.

Keywords:
Bromelain-based debridement,
Diabetic foot ulcers,
Wound healing,
Enzymatic debridement,
Brian McCurdy

Case Series: Evaluating Aiodine™ for Severe Traumatic Wounds

A recent case series published in Wounds International explores the preliminary outcomes of using Aiodine™, a novel topical iodine-based formulation, in the management of severe traumatic wounds. Conducted at the Wound Department of the First Affiliated Hospital of Hainan Medical University in Haikou, China, the study involved four patients presenting with various types of severe wounds.

Key Findings:

• Significant improvements in wound healing were observed within two weeks or less.
• Substantial reductions in infection rates were noted across all cases.
• No adverse effects related to Aiodine™ application were reported.

These findings suggest that Aiodine™ may serve as a promising therapeutic agent in wound care. However, the authors emphasize the need for further validation through larger, randomized, double-blind, placebo-controlled clinical trials to confirm these preliminary outcomes.

Read the full article on the Wounds International website.

Keywords:
Aiodine,
Iodine-based formulations,
Traumatic wound management,
Infection control,
Cheng Shaowen,
Yao Jiangling,
Fu Sheng,
Patrick Fernandez,
Shabbir Moochhala

WRAHPS: New Guidelines Aim to Standardize Preclinical Wound Research

In an effort to enhance the quality and reproducibility of preclinical wound healing studies, a consortium of experts has introduced the Wound Reporting in Animal and Human Preclinical Studies (WRAHPS) guidelines. Published in the January-February 2025 issue of Wound Repair and Regeneration, these guidelines provide comprehensive checklists and reporting templates for commonly used animal and human ex vivo wound models.

Key Highlights:

• Standardization of Reporting: WRAHPS offers detailed checklists to ensure consistent documentation of experimental conditions, facilitating transparency and comparability across studies.
• Enhancing Translational Research: By addressing the variability in preclinical models and methodologies, the guidelines aim to bridge the gap between laboratory findings and clinical applications.
• Comprehensive Coverage: The guidelines encompass various aspects of preclinical studies, including animal species selection, wound induction methods, assessment techniques, and data analysis protocols.

The development of WRAHPS involved collaboration among researchers from institutions such as the University of Miami, University of Pennsylvania, The Ohio State University, and the University of Illinois Chicago. The initiative underscores the importance of meticulous reporting in advancing wound care research and ultimately improving patient outcomes.

Read the full article on the PubMed Central website.

Keywords:
Preclinical wound models,
WRAHPS guidelines,
Standardized reporting,
Translational research,
Animal models in wound healing,
Human ex vivo models

The Complexities of Managing an Ever-Growing Problem of Chronic Wounds

In the latest issue of Wound Practice and Research, editors Peta Tehan and Zlatko Kopecki delve into the multifaceted challenges of chronic wound management in Australia. The issue underscores the increasing prevalence of chronic wounds and the necessity for a comprehensive, multidisciplinary approach to address this growing healthcare concern.

Key highlights include:

• Redefining Research Priorities: A consensus study by Finlayson et al. identifies critical areas for chronic wound research, emphasizing pain management, venous leg ulcer compression therapy, and pressure injury management. Notably, diabetic foot ulcers and pressure injury care emerged as top priorities among experts for prevention and management strategies.
• Patient-Centric Approaches: A scoping review by Pennisi et al. advocates for integrating patients into chronic disease management frameworks to prevent venous leg ulcer recurrence. The study calls for a shift in language and focus, promoting community integration and multidisciplinary collaboration.
• Early Detection and Intervention: Research by O’Connor et al. highlights the prevalence and risk factors of chronic lower limb oedema in older populations, stressing the importance of early detection to initiate timely interventions. Additionally, a case study by Astrada demonstrates the utility of ultrasonography in identifying subcutaneous scarring post-healing of infected diabetic foot ulcers, facilitating appropriate management strategies.
• Innovative Treatment Modalities: Kruschwitz and Probst present a retrospective analysis on managing exudate in pressure injuries using multipurpose dressings, resulting in significant wound area reduction. Furthermore, Hulsdunk and Haesler discuss evidence supporting low-level laser therapy for venous leg ulcer healing.

This comprehensive issue serves as a valuable resource for clinicians and researchers, offering insights into current challenges and advancements in chronic wound care.

Read the full article on the Wound Practice and Research website.

Keywords:
Chronic wounds,
Venous leg ulcers,
Pressure injuries,
Diabetic foot ulcers,
Compression therapy,
Low-level laser therapy,
Multidisciplinary care,
Patient-centered care,
Ultrasonography,
Oedema management

Challenging Historic Practice in Leg and Foot Care: Ensuring Compression is the Default Therapy for Lower Leg Wounds

The Society of Tissue Viability, in collaboration with the Legs Matter coalition, is hosting a free full-day educational session on June 10, 2025, aimed at transforming the approach to lower limb wound care. The event focuses on advocating for compression therapy as the default treatment for various lower leg wounds, moving beyond its traditional association with venous leg ulcers.

Despite the well-documented benefits of compression therapy, its application remains inconsistent due to entrenched practices and a lack of comprehensive education. This study day seeks to address these gaps by presenting evidence-based strategies and challenging outdated methodologies that hinder optimal patient care.

Key topics include:

• Utilizing compression in lower limb trauma management within plastic surgery settings – Stephanie Brown, Clinical Practitioner, Royal Stoke Hospital
• Applying compression therapy in cases of combined arterial and venous insufficiency – Annie Clothier, Vascular Clinical Nurse Specialist, Aneurin Bevan University Health Board
• Implementing compression for patients with diabetic foot ulceration – Jayne Robbie, Senior Lecturer in Diabetes Care and Specialist Podiatrist, Birmingham City University and University Hospitals Birmingham NHS Trust
• Personalizing compression therapy to meet individual patient needs – Kate Williams, Associate Director of Wound Care, Accelerate CIC
• Living better with lymphoedema – Matt Hazledine, Founder of Lymph United

This event is tailored for healthcare professionals involved in lower limb wound care, including community nurses, podiatrists, tissue viability specialists, vascular and plastic surgery practitioners, dermatology and lymphoedema services, and general practitioners.

Read the full article and register for the event on the Society of Tissue Viability website.

Keywords:
Compression therapy,
Lower leg wounds,
Venous leg ulcers,
Diabetic foot ulceration,
Lymphoedema,
Society of Tissue Viability,
Legs Matter coalition

Tell Me Your Story – The Undaunted Spirit of Patients with Chronic Wounds

In a heartfelt blog post, Dr. Caroline Fife shares a personal narrative that underscores the resilience of patients with chronic wounds. Recounting a challenging period in her life, she describes returning to work after a family health crisis and encountering a quadriplegic patient with severe pressure ulcers. Despite his condition, he greeted her with a smile and a simple request: “Hi Dr. Fife, isn’t it a beautiful day today? By the way, would you scratch my nose?”

This encounter profoundly impacted Dr. Fife, leading her to establish the “Undaunted Spirit” award to honor patients who inspire through their courage and positivity. She emphasizes that patient stories are invaluable for:

• Highlighting everyday heroes who refuse to be defined by their conditions
• Identifying gaps in medical knowledge and treatment options
• Exposing issues in healthcare policy and delivery
• Providing opportunities to improve clinical practices and research methodologies

Dr. Fife invites both patients and clinicians to share their stories, aiming to use these narratives to enhance the art and practice of chronic wound care.

Read the full article on the Caroline Fife, MD website.

Keywords:
Chronic wounds,
Patient stories,
Undaunted Spirit award,
Caroline Fife,
Pressure ulcers,
Healthcare policy

Incidence of Charcot Arthropathy: A Nationwide Study #ActAgainstAmputation

A recent nationwide study from Denmark, spanning from 2000 to 2021 and involving over 265,000 patients with diabetes, reveals a paradoxical trend in Charcot arthropathy cases. While the absolute number of Charcot cases increased significantly over the study period (Kendall’s tau = 0.6, p < 0.0005), the incidence rate per capita among people with diabetes actually declined (Kendall’s tau = -0.6, p = 0.0005) [Source].

This suggests that, although more individuals are developing Charcot arthropathy due to the increasing prevalence of diabetes, the individual risk of developing this complication is decreasing. Improved management of diabetes and neuropathy may be contributing factors to this decline in individual risk.

Notably, the study found no significant regional differences in incidence across Denmark’s five health regions, nor any measurable impact from the COVID-19 pandemic or the nurses’ strike of 2021. This underscores the resilience of Denmark’s multidisciplinary care infrastructure in managing diabetic complications.

These findings highlight the importance of robust public health systems and early intervention strategies in mitigating the disabling effects of diabetic complications like Charcot arthropathy.

Read the full article on the Diabetic Foot Online website.

Keywords:
Charcot arthropathy,
Diabetic neuropathy,
Denmark healthcare,
Public health infrastructure,
Diabetes management,
Epidemiology

Nutrition and Wound Healing: Practical Takeaways for Wound Care Practitioners

At WoundCon Spring 2025, experts Dr. Nancy Munoz and Dr. Mary Litchford emphasized the pivotal role of nutrition in wound healing. They highlighted that optimal healing is not solely reliant on topical treatments but also heavily depends on the patient’s nutritional status.

Macronutrients:

• Carbohydrates: Serve as the primary energy source, supporting cellular activities and the inflammatory response. Emphasis should be on high-fiber, complex carbohydrates like whole grains, legumes, fruits, and vegetables.
• Fats: Unsaturated fats, found in olive oil, nuts, and seeds, maintain cellular integrity and reduce inflammation. Saturated and trans fats should be minimized due to their pro-inflammatory effects.
• Proteins: Essential for tissue regeneration and immune defense. Patients may require 1.25 to 1.5 grams of protein per kilogram of body weight, increasing to 2.0 grams/kg in severe cases. Both animal-based and well-planned plant-based proteins are beneficial.

Read the full article on the WoundSource website.

Keywords:
Nutrition,
Wound Healing,
Macronutrients,
Micronutrients,
Hydration,
Nancy Munoz,
Mary Litchford

Ontario Begins Funding Total Contact Casting—But Is It Enough?

Three years ago, WoundCareWeekly highlighted a troubling reality in Ontario: while thousands of diabetic patients were undergoing lower-limb amputations annually, the province refused to publicly fund proven offloading treatments like total contact casting (TCC). In that post, we quoted Registered Nurses’ Association of Ontario (RNAO) CEO Doris Grinspun, who memorably criticized the government’s inaction: “We’re willing to pay for the amputations but we’re not willing to pay for the prevention.”

Today, we’re pleased to report that the province has taken a step forward.

Ontario’s Ministry of Health, following recommendations by Health Quality Ontario (HQO), has committed to funding three forms of offloading devices: fibreglass total contact casts, removable cast walkers, and irremovable cast walkers for patients with neuropathic diabetic foot ulcers. A $8 million provincial investment, announced in 2023, will roll out over three years and aims to improve access to these devices through Local Health Integration Networks and Aboriginal Health Access Centres.

The funding covers offloading systems that cost between $150 and $620—minimal compared to the estimated $74,000 per limb spent on amputations. More importantly, this policy aligns with international best practices that emphasize offloading as the single most critical component in healing plantar diabetic foot ulcers.

But as with many bureaucratic victories, implementation lags behind intention. Access to trained professionals capable of applying TCCs, inconsistencies in supply chains, and variability in clinical awareness mean many patients still aren’t receiving the gold standard in care.

We commend Ontario for making this move—but the real test will be in delivery. We’ll continue to follow how this funding translates to outcomes and whether it lives up to the promise of reducing preventable amputations in a system that can no longer afford inaction.

For more background, read our original editorial: “We’ll Pay for the Amputation, But Not the Prevention” 

Keywords:
Total Contact Casting,
Diabetic Foot Ulcers,
Ontario Health Policy,
Offloading Devices,
Doris Grinspun,
RNAO,
Amputation Prevention

Age Characteristics of Patients With Type 2 Diabetic Foot Ulcers and Predictive Risk Factors for Lower Limb Amputation: A Population-Based Retrospective Study

A population-based retrospective study published in the Journal of Diabetes Research analyzed data from 918 patients with type 2 diabetic foot ulcers (DFUs) treated between 2017 and 2023 at The First Affiliated Hospital of Wannan Medical College in Wuhu, China. The study aimed to investigate age-related characteristics and identify key risk factors associated with lower limb amputation in this patient population.

The findings revealed that the majority of DFU patients were aged between 50 and 59 years, with a notable peak in mortality observed among those aged 70 to 79. Logistic regression analysis identified several significant predictors for lower extremity amputation, including a history of prior amputation, presence of vascular complications, infection sites, and hemoglobin levels. Specifically, a history of amputation and low hemoglobin were strongly associated with major amputations.

These insights underscore the importance of early identification and management of risk factors to prevent severe outcomes in patients with DFUs, particularly in middle-aged and older populations.

Read the full article on the Journal of Diabetes Research website.

Keywords:
Type 2 diabetes,
Diabetic foot ulcers,
Lower limb amputation,
Risk factors,
Yuanying Yao,
Lei Chen,
Yu Qian

Clinical Outcomes of Hyperbaric Oxygen Therapy for Diabetic Foot Ulcers: A Systematic Review

A systematic review published in Cureus evaluated the effectiveness of hyperbaric oxygen therapy (HBOT) in treating diabetic foot ulcers (DFUs). The review analyzed six studies encompassing a total of 391 patients to assess HBOT’s impact on healing rates, ulcer dimensions, and amputation outcomes.

The majority of the studies indicated that HBOT led to lower rates of major amputations, improved ulcer healing, and reduced ulcer dimensions compared to standard care. However, one study found no significant differences in amputation rates or long-term wound healing between groups. The review also noted variations in methodological rigor across the included studies, with selection bias from inconsistent patient allocation being a common limitation in observational studies, potentially distorting comparisons.

These findings suggest that HBOT may be a beneficial adjunctive treatment for DFUs, but further high-quality, randomized controlled trials are needed to confirm its efficacy and address existing methodological concerns.

Read the full article on the Cureus website.

Keywords:
Hyperbaric oxygen therapy,
Diabetic foot ulcers,
Amputation prevention,
Wound healing,
Systematic review,
Ujwala Damineni,
Shravani Divity,
Sri Ram Charan Gundapaneni,
Tejaswi Vadde

Fish Skin Grafts Show Promise for Improved Diabetic Foot Ulcer Healing

A randomized prospective trial, as reported by the American College of Surgeons, has demonstrated that decellularized, lyophilized fish skin grafts derived from Atlantic cod may enhance healing in patients with high-risk diabetic foot ulcers (DFUs) involving deep structures such as muscle, bone, and joints. The study compared the efficacy of fish skin grafts to standard wound care, which typically includes debridement, cleansing, and skin grafting.

Results indicated that 44% of patients treated with fish skin grafts achieved complete healing at 16 weeks, compared to 26% in the standard care group. These findings suggest that fish skin grafts could offer a more effective treatment option for complex DFUs, potentially reducing healing time and improving patient outcomes. However, accompanying editorial commentary emphasized the need for further research into the cost-effectiveness of this treatment approach, given the significant expense associated with the grafts.

Read the full article on the American College of Surgeons website.

Keywords:
Fish skin grafts,
Diabetic foot ulcers,
Atlantic cod,
Standard wound care,
Randomized prospective trial,
Cost-effectiveness

Dardari D, Piaggesi A, Potier L, et al. Intact Fish Skin Graft to Treat Deep Diabetic Foot Ulcers. NEJM Evid. 2024;3(12).

Castellani L, Arruda S. Hooked on Healing—Fish Skin Grafts for Diabetic Foot Ulcers. NEJM Evid. 2024;3(12).

New Protocols for Treating Patients with Xylazine Wounds

A multidisciplinary team at the University of Pittsburgh Medical Center (UPMC) has developed comprehensive clinical protocols to manage hospitalized patients exposed to xylazine—a veterinary sedative increasingly found in the unregulated opioid supply. Xylazine exposure has been associated with severe complications, including difficult-to-manage withdrawal symptoms and necrotic skin ulcerations prone to infection and chronicity.

UPMC’s toxicology testing revealed a five-fold increase in patient samples testing positive for xylazine between 2019 and 2021, highlighting the growing impact of this substance. In response, the team implemented detailed treatment protocols, published in the Substance Use & Addiction Journal, emphasizing standardized, evidence-based, and trauma-informed approaches to care.

Led by Dr. Raagini Jawa, MD, MPH, FASAM, along with co-authors Dr. Margaret Shang, MD, MS, and Dr. Ilana Hull, MD, MSc, the team convened clinicians from various specialties—including addiction medicine, toxicology, emergency medicine, psychiatry, and plastic surgery—to address the complex needs of patients affected by xylazine. The protocols aim to improve patient outcomes through coordinated, multidisciplinary care.

Read the full article on the Medical Xpress website.

Keywords:
Xylazine,
Necrotic skin ulcerations,
Withdrawal management,
Multidisciplinary care,
UPMC,
Raagini Jawa,
Margaret Shang,
Ilana Hull

Medicare National Correct Coding Initiative Medically Unlikely Edits: Myth and Mystery

In the May 2025 issue of Advances in Skin & Wound Care, Kathleen D. Schaum, MS, addresses prevalent misconceptions surrounding the Medicare National Correct Coding Initiative (NCCI) Medically Unlikely Edits (MUEs). MUEs, introduced in 2007, are designed to prevent inappropriate Medicare payments by setting maximum units of service (UOS) that a provider can report for a single beneficiary on a single day.

Schaum emphasizes that MUEs are coding edits, not determinations of medical necessity. Therefore, denials based on MUEs are not subject to appeal through medical necessity channels. She also clarifies that providers should not circumvent MUEs by splitting services across multiple dates to avoid edit triggers, as this practice is discouraged and may lead to compliance issues.

The article highlights the existence of three separate MUE tables published by CMS: Practitioner Services MUE, DME Supplier Services MUE, and Facility Outpatient Hospital Services MUE. However, not all codes have associated MUEs, and the absence of an MUE does not imply unlimited billing for a service.

Read the full article on the Advances in Skin & Wound Care website.

Keywords:
Medically Unlikely Edits,
National Correct Coding Initiative,
Medicare compliance,
Coding edits,
CMS guidelines,
Wound care billing
Note: The above synopsis is based on the article’s content and available information. For a comprehensive understanding, please refer to the full article.

Bromelain-Based Debridement Versus Collagenase Ointment Debridement of Venous Leg Ulcers: Post Hoc Analysis of the ChronEx Trial

A recent post hoc analysis of the ChronEx trial, published in Wounds, compared the efficacy of bromelain-based enzymatic debridement (BBD) with collagenase ointment (CO) in treating venous leg ulcers (VLUs). The study aimed to assess which method more effectively achieved complete debridement and granulation within a two-week period.

The analysis included 46 patients with VLUs who were treated with either BBD or CO. Results indicated that a higher proportion of wounds treated with BBD achieved complete debridement and granulation at two weeks compared to those treated with CO. Additionally, the median time to complete debridement and granulation was shorter in the BBD group, suggesting a more rapid wound healing process.

These findings suggest that BBD may offer a more efficient alternative to CO for enzymatic debridement in VLUs, potentially leading to faster wound healing and improved patient outcomes.

Read the full article on the Wounds Journal website.

Keywords:
Bromelain-based debridement,
Collagenase ointment,
Enzymatic debridement,
Venous leg ulcer,
ChronEx trial,
Wound healing

Note: The above synopsis is based on the article’s content and available information. For a comprehensive understanding, please refer to the full article.

Anti-Biofilm Wound Dressing Market: Steady Growth Expected, Reaching US$ 2,132.5 Million by 2032

The global anti-biofilm wound dressing market is experiencing significant growth, driven by the increasing prevalence of chronic and acute wounds, advancements in wound care technology, and heightened awareness of biofilm-related infections. Biofilms, protective clusters of bacteria, pose challenges in wound healing by leading to chronic infections and delayed recovery. Anti-biofilm wound dressings are specifically designed to disrupt these biofilms, promoting better healing outcomes and reducing infection risks.

According to a report by Persistence Market Research, the market was valued at US$ 1,001.6 million in 2025 and is projected to reach US$ 2,132.5 million by 2032, growing at a CAGR of 11.4%. North America currently holds a significant share of the market, attributed to its robust healthcare infrastructure and high incidence of chronic diseases. The Asia-Pacific region is anticipated to witness the fastest growth during the forecast period, fueled by increasing healthcare access, medical tourism, and demand for advanced wound care products in emerging markets like India and China.

Key market segments include chemical-based, physical-based, and biological-based wound dressings. Chemical-based dressings, containing agents like ionic silver, iodine, and EDTA, are expected to dominate due to their broad-spectrum antimicrobial properties. Physical-based dressings, such as hydrocolloids and hydrogels, provide a moist environment to accelerate tissue regeneration. Biological-based dressings utilize collagen and growth factors to support healing, particularly in chronic wounds like diabetic foot ulcers and pressure ulcers.

Leading companies in the market, including ConvaTec, Smith & Nephew PLC, and Mölnlycke Health Care, are engaging in mergers and acquisitions to expand their product portfolios and market reach.

Read the full article on the openPR website.

Keywords:
Anti-biofilm wound dressing,
Biofilm infections,
Chronic wounds,
Acute wounds,
Chemical-based dressings,
Physical-based dressings,
Biological-based dressings,
ConvaTec,
Smith & Nephew PLC,
Mölnlycke Health Care

Insulin and Metformin Combo Aids Diabetic Foot Ulcer Healing, New Study Finds

A recent study by researchers at Michigan State University and South Shore Hospital has uncovered that combining insulin injections with oral metformin therapy can enhance healing in patients with diabetic foot ulcers (DFUs). The study found that this combination increases the concentration of metformin at the wound site, potentially accelerating the healing process.

Dr. Morteza Mahmoudi, an associate professor at MSU’s College of Human Medicine, noted that their analysis of wound exudates revealed the presence of metformin, suggesting that the combined therapy allows metformin to reach the wound area more effectively. This discovery indicates a synergistic effect between insulin and metformin in promoting wound healing.

Co-researcher Dr. Lisa Gould, a plastic surgeon and wound care clinician at South Shore Hospital and a clinical associate professor at Brown University, emphasized the clinical implications of these findings. The study suggests that clinicians could consider prescribing both insulin and metformin not only for glycemic control but also to enhance local wound healing processes in patients with chronic DFUs.

Read the full article on the Medical Xpress website.

Keywords:
Diabetic foot ulcers,
Insulin therapy,
Metformin,
Wound healing,
Combination therapy,
Michigan State University,
South Shore Hospital

Note: The above synopsis is based on the article’s content and available information. For a comprehensive understanding, please refer to the full article.

Unravelling the Cardio-Renal-Metabolic-Foot Connection in People with Diabetes-Related Foot Ulceration: A Narrative Review

• Nick S. R. Lan,
• Girish Dwivedi,
• P. Gerry Fegan,
• Fran Game &
• Emma J. Hamilton

A recent narrative review published in Cardiovascular Diabetology explores the interconnectedness of cardiovascular, renal, metabolic, and foot complications in individuals with diabetes-related foot ulceration (DFU). The authors propose a “cardio-renal-metabolic-foot” framework, highlighting shared pathophysiological mechanisms that link DFU with cardiovascular and renal diseases.

The review emphasizes that systemic inflammation and infection associated with DFU may contribute to the development and progression of cardiovascular and renal conditions. Conversely, existing cardiovascular and renal diseases can exacerbate the risk and severity of DFU, indicating a bidirectional relationship. The authors advocate for a holistic, multidisciplinary approach to managing DFU, incorporating early screening and management of cardiovascular and kidney diseases.

Emerging therapies, such as sodium-glucose co-transporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and non-steroidal mineralocorticoid receptor antagonists, have shown promise in improving cardiovascular and renal outcomes in people with type 2 diabetes. While dedicated research in DFU populations is needed, these therapies could potentially address multiple aspects of the cardio-renal-metabolic-foot connection.

Read the full article on the Cardiovascular Diabetology website.

Keywords:
Diabetes-related foot ulceration,
Cardio-renal-metabolic connection,
Systemic inflammation,
Multidisciplinary care,
SGLT2 inhibitors,
GLP-1 receptor agonists,
Mineralocorticoid receptor antagonists

Note: The above synopsis is based on the article’s abstract and available information. For a comprehensive understanding, please refer to the full article.

UT Health San Antonio Study Uncovers Key Risk Factors for Diabetic Foot Infection Recurrence

A recent study conducted by researchers at UT Health San Antonio has identified significant risk factors contributing to the recurrence of diabetic foot infections. Published in the International Wound Journal in November 2024, the study analyzed eight years of patient data to understand why nearly half of patients treated for diabetic foot infections experience reinfection within a year.

Led by Dr. Lawrence A. Lavery, DPM, MPH, a specialist in diabetic foot complications and professor of orthopaedics, the research reviewed records of 294 patients hospitalized for moderate to severe diabetic foot infections. The findings revealed that patients with wounds unhealed after three months were three times more likely to experience reinfection. Additionally, those with bone infections had more than twice the risk compared to patients with only soft tissue infections.

Dr. Lavery emphasized the importance of wound healing in preventing reinfections, stating, “When your wound fails to heal or you develop another wound, the clock starts ticking.” The study also highlighted that patients with unhealed wounds faced longer healing times, increased hospital readmissions, and extended hospital stays, underscoring the need for early intervention and comprehensive care strategies.

Read the full article on the UT Health San Antonio Newsroom.

Keywords:
Diabetic foot infection,
Infection recurrence,
Wound healing,
Bone infection,
Peripheral neuropathy,
UT Health San Antonio,
Lawrence A. Lavery

Note: The above synopsis is based on the article’s content and available information. For a comprehensive understanding, please refer to the full article.

Fibroblast Technology Developed for Diabetic Foot Ulcers and Chronic Wounds

FibroBiologics, in collaboration with Charles River, has announced the completion of a master cell bank for a novel fibroblast-based therapy aimed at treating chronic wounds, including diabetic foot ulcers (DFUs). The product, designated CYWC628, utilizes a spheroid approach to deliver fibroblast cells topically, promoting wound healing by releasing essential growth factors and cytokines.

According to Dr. Hamid Khoja, Chief Scientific Officer at FibroBiologics, “Fibroblasts are involved in every single stage of the wound healing process.” He notes that chronic wounds like DFUs often fail to heal due to cellular senescence, and this new therapy aims to address that by rejuvenating the wound environment.

CYWC628 has passed all required safety testing, and clinical trials are scheduled to commence in the second quarter of 2025. The 12-week study will evaluate the product’s efficacy in promoting healing in patients with chronic wounds.

Read the full article on the Healio website.

Keywords:
Fibroblast therapy,
Chronic wounds,
Diabetic foot ulcers,
CYWC628,
Wound healing,
Cell-based therapy,
Growth factors,
Clinical trials,
Cellular senescence

Advancements in Diabetic Foot Ulcer Research, published in Heliyon in 2024, offers a comprehensive overview of current treatment strategies for diabetic foot ulcers (DFUs). It systematically compares various therapeutic approaches, highlighting their respective advantages and limitations.

ShuHui Wu, ZhongSheng Zhou, Yang Li, Jinlan Jiang

Key Highlights:

• Treatment Modalities: The article examines a range of treatments, including wound dressings, negative pressure wound therapy, hyperbaric oxygen therapy, and advanced therapies like stem cell applications.

• Advantages and Limitations: Each treatment is assessed for its efficacy, accessibility, cost-effectiveness, and potential side effects. For instance, while hyperbaric oxygen therapy shows promise in enhancing wound healing, it may not be widely accessible due to cost and equipment requirements.ScienceDirect

• Clinical Implications: The review underscores the importance of personalized treatment plans, considering patient-specific factors such as comorbidities, ulcer severity, and resource availability.

This article serves as a valuable resource for healthcare professionals seeking to understand the evolving landscape of DFU management and emphasizes the need for continued research to optimize patient outcomes.ScienceDirect

For a more in-depth understanding, you can access the full article here: ScienceDirect.

Keywords
Diabetic foot ulcers, Mesenchymal stem cells, Exosomes

Evaluation of Shear Force Redistribution and Pressure Reduction in a Novel Support Surface for Pressure Injury Prevention

A recent study published in the Advances in Skin & Wound Care journal evaluated the effectiveness of a novel support surface designed to redistribute shear forces and reduce pressure, aiming to prevent pressure injuries (PIs). The research focused on assessing how this innovative surface performs in mitigating factors that contribute to the development of PIs, particularly in high-risk areas like the sacrum and heels.

The study utilized anatomically accurate models and clinically relevant pressure tests to compare the new support surface against existing options. Findings indicated that the novel surface significantly reduced peak pressure and shear forces, suggesting its potential in enhancing patient care and preventing PIs.

These results highlight the importance of incorporating advanced support surfaces into clinical practice to improve patient outcomes. The study advocates for further clinical trials to validate these findings in real-world settings.

Read the full article on the Advances in Skin & Wound Care website.

Healing with Intelligence: SAWC 2025 Keynote Highlights Transformative Role of AI

At the 2025 Symposium on Advanced Wound Care (SAWC) Spring meeting in Grapevine, Texas, the keynote titled “Healing with Intelligence” spotlighted the transformative role of artificial intelligence (AI) in wound care. Led by Dr. Eric Lullove, Chief Medical Officer at the West Boca Center for Wound Healing, the session emphasized a paradigm shift from reactive to predictive wound management.

Dr. Lullove noted that chronic wounds, affecting over 6.5 million Americans each year, are not just local issues but markers of systemic inefficiencies. AI, he argued, can help clinicians move beyond traditional documentation and embrace smarter diagnosis, streamlined workflows, and improved clinical decision-making.

The panel covered key applications of AI in wound care, including predictive analytics, automated documentation, and real-time clinical decision support. These tools are designed to augment rather than replace clinician judgment. However, a live audience poll revealed that nearly 70% of attendees had limited exposure to AI in practice—highlighting the urgent need for education and accessible integration tools.

Challenges discussed included data security, regulatory compliance, and bias in AI models—especially those trained on narrow patient demographics. Panelists emphasized the importance of designing AI that enhances care without disrupting workflows, and the ethical responsibility to ensure fairness across diverse populations.

The session concluded with a clear call to action: wound care professionals must help lead the integration of AI, ensuring it is used not only intelligently, but humanely. The future of wound care, the panel agreed, lies in combining data-driven insights with hands-on compassion.

Read the full coverage from SAWC Spring 2025 at HMP Global Learning Network.

The Many Advantages of Buying from U.S.-Based Total Contact Casting (TCC) Manufacturers

As supply chains continue to shift and tariffs reshape global trade, healthcare providers are taking a closer look at where their medical products are made — and for good reason. When it comes to Total Contact Casting (TCC) kits, working with U.S.-based manufacturers offers multiple benefits that go far beyond product availability.

🇺🇸 Supporting U.S. Jobs and Economic Growth

One of the primary goals behind recent U.S. tariffs on imported goods — especially from countries like China and Mexico — is to incentivize domestic production and bring jobs back to the United States. By sourcing TCC kits from American companies, clinics and hospitals contribute to this effort, helping strengthen the U.S. manufacturing base and create employment in logistics, packaging, and assembly sectors.

📦 Reliable Supply Chains and Faster Fulfillment

U.S.-based TCC manufacturers like M-Med benefit from being located within national logistics hubs. That means faster fulfillment, fewer customs delays, and greater supply chain stability — even during international disruptions. With wound care patients requiring timely interventions, every day of delay can matter.

💰 Predictable Pricing Without Tariff Surprises

Imported medical devices from Mexico and other countries may face tariffs of up to 25% if they do not meet strict USMCA compliance standards. While some products are exempt, not all medical devices qualify — and compliance must be proven. Domestic manufacturers avoid these pricing uncertainties, offering more consistent and transparent cost structures for purchasing departments.

🛠 Quality, Oversight, and Responsiveness

U.S.-based manufacturers operate under FDA guidelines and often have shorter feedback loops with customers. That means higher quality control, quicker responses to clinical feedback, and greater flexibility when it comes to custom orders or support.

✅ The M-Med Advantage

M-Med’s Total Contact Casting kits are manufactured and assembled in the Southeastern U.S., with more padding and more components than standard kits. As a family-owned business, we prioritize fast delivery, dependable quality, and close relationships with the wound care professionals we serve.

In a time when sourcing and supply decisions carry long-term implications, buying American-made TCC products isn’t just a smart business move — it’s an investment in quality care and domestic resilience.

Disclosure: M-Med is a sponsor of WoundCareWeekly. While editorial content is independently written, M-Med supports our mission to educate and connect the wound care community.

Playing the Long Game with Diabetes: Prioritizing Foot Health

The American Podiatric Medical Association (APMA) emphasizes the critical importance of foot health in diabetes management. Individuals with Type 1 or Type 2 diabetes face a heightened risk of serious foot complications, including infections and amputations. APMA’s “Playing the Long Game with Diabetes” campaign advocates for early adoption of healthy habits to prevent such outcomes.APMA MAIN+7APMA MAIN+7APMA MAIN+7APMA MAIN+3APMA MAIN+3APMA MAIN+3

Key recommendations include annual visits to an APMA-member podiatrist, or at minimum, regular foot checks by a primary care provider if podiatric access is limited. The APMA provides a suite of resources to support patients in maintaining foot health:APMA MAIN

• Daily Foot Exams: Guidance on conducting simple daily inspections to detect early signs of complications.

• Educational Materials: Tip sheets and videos featuring podiatrists sharing insights on diabetes-related foot care.

• Product Recommendations: A list of APMA Seal-approved footwear and products designed for diabetic foot care.APMA MAIN+1APMA MAIN+1

• Community Engagement: Encouragement to join conversations on social media using the hashtag #PlaytheLongGame.APMA MAIN+4APMA MAIN+4APMA MAIN+4

These resources aim to empower individuals with diabetes to take proactive steps in managing their foot health, thereby reducing the risk of complications.APMA MAIN

Explore the full suite of resources here: APMA Diabetes Awareness

About the Author: Dr. Savannah Santiago, DPM

Dr. Savannah Santiago is a first-year podiatric medicine and surgery resident at Ascension St. Vincent Hospital in Indianapolis. A 2024 graduate of Western University of Health Sciences College of Podiatric Medicine, she holds a B.S. in Biomedical Sciences and Spanish Language and Culture from the University of Colorado Colorado Springs, where she also competed in NCAA cross country and track and field.Pod Patrol+5LinkedIn+5Ascension Medical Education+5WesternU News+2cdn2.podiatry.com+2Ascension Medical Education+2

Dr. Santiago’s personal experiences, including managing her own diabetes diagnosis at 19 and overcoming sports-related injuries, have fueled her passion for podiatry. Her clinical interests encompass reconstructive surgery, limb salvage, pediatric podiatry, sports medicine, and inpatient care.Ascension Medical Education

An active contributor to the field, she authors the “Sole Purpose” blog on PRESENT Podiatry and has been featured on the Pod Patrol podcast. Dr. Santiago also serves as the first Resident Liaison for the American College of Podiatric Medicine (ACPM). Outside the clinic, she enjoys trail running, rollerblading, and exploring farmers markets.session.podiatry.com+4Pod Patrol+4Podiatry+4InstagramAscension Medical Education

Note: This bio is intended for educational purposes and to inform readers about Dr. Santiago’s contributions to the field of podiatric medicine.

Wound Remodelling Strategies for Challenging Wound Topographies

Even with optimal debridement, certain wounds resist healing due to unfavorable base elevations or edge configurations. In this insightful article, Igor Melnychuk explores advanced wound remodelling techniques designed to overcome these barriers and promote effective closure.

Key strategies discussed include:

• Base Contouring: Lowering elevated wound beds to align with the periwound skin, facilitating keratinocyte migration.woundsinternational.com

• Edge Resection: Trimming vertical or undermined edges at a 45° angle to eliminate impediments to epithelialization.woundsinternational.com+1woundsinternational.com+1

• Innovative Techniques: Introducing methods like edge trenching, soap scrap, and parallel pocket incisions, inspired by grafting principles, to address complex wound geometries without extensive tissue removal.woundsinternational.com

These approaches are particularly beneficial for wounds exhibiting features such as epiboly, undermining, or raised bases, where traditional healing processes are compromised.

Read the full article here: Wound Remodelling: Approaches and Techniques Aimed at Closure of Wounds with Unfavourable Base or Edges

About the Author: Igor Melnychuk

Igor Melnychuk is a dedicated wound care specialist with extensive experience in managing complex and hard-to-heal wounds. His work focuses on developing and implementing innovative techniques to enhance wound healing outcomes. Through his research and clinical practice, Igor contributes significantly to the advancement of wound care methodologies.

Note: This synopsis is intended for educational purposes and to inform wound care professionals about recent advancements in wound management strategies.

for the Appropriateness of Wound Treatments?

In this thought-provoking article, the author challenges wound care professionals to critically evaluate the appropriateness of their treatment choices. Despite advances in technology and science, outdated or non-evidence-based approaches remain common in clinical practice. The author introduces three practical “litmus test” questions to guide treatment decisions: 1) What is the rationale for this treatment? 2) What does the science and evidence say? and 3) Could this plan of care be defended in court? Through clear examples—like the misuse of NPWT on necrotic wounds or unnecessary topical antibiotics—the article underscores the importance of logic, clinical evidence, and legal defensibility in creating effective, modern wound care plans … full article

About the author:

About the Author: Bill Richlen, PT, WCC, DWC (1970–2024)

Bill Richlen was a respected physical therapist and wound care educator with over 25 years of clinical and teaching experience. A graduate of the University of Wisconsin–Madison, he specialized in advanced wound care and debridement across long-term care, outpatient, rehab, and home health settings.

He co-founded Wound Care Gurus, serving as CEO and providing evidence-based education and consulting nationwide. Bill was also a long-time instructor with the Wound Care Education Institute (WCEI), known for his engaging teaching style and commitment to practical, science-driven care. His legacy lives on through the thousands of clinicians he mentored.

A recent economic evaluation using a Markov model assessed the cost-effectiveness of dehydrated human amnion/chorion membrane (DHACM) for Medicare beneficiaries with venous leg ulcers (VLUs). The study compared DHACM—applied following recommended timing and frequency—to no advanced treatment (NAT) over three years, using real-world claims from over 530,000 patients. Results showed that DHACM not only saved $170 per patient but also improved quality-adjusted life years (QALYs), producing a net monetary benefit of $1,178. The treatment was cost-effective in over 63% of simulations and linked to lower recurrence rates. With chronic wounds placing a heavy and growing burden on Medicare—VLUs alone cost $14.9 billion annually—these findings support DHACM as a superior, cost-saving strategy. Providers and payers are encouraged to prioritize DHACM in wound care formularies to improve outcomes and reduce system-wide costs … read more

The authors:

1. William H. Tettelbach, MD, FACP, FIDSA, FUHM, CWSP

Dr. Tettelbach is board-certified in Undersea & Hyperbaric Medicine, Infectious Diseases, and Internal Medicine. He has held leadership roles at MiMedx, OnSite Advanced Care, and RestorixHealth, and serves as an adjunct professor at Duke University School of Medicine. ​WICE Radiology+8Press Release Hub+8ORCID+8

• ORCID Profile

2. Vickie R. Driver, DPM, MS, FACFAS

Dr. Driver is a Professor at Washington State University School of Medicine and the Founding Chair of the Board of Directors for the Wound Care Collaborative Community. She has served as System-Wide Medical Director of Wound Care and Hyperbaric Centers at INOVA Healthcare and is a Fellow of the Royal College of Physicians and Surgeons-Glasgow. ​hmpglobalevents.com+5woundcarecc.org+5woundcarecc.org+5reddressmedical.com+4sawcf.eventscribe.net+4Maggie Online Library+4

• Wound Care Collaborative Community Profile

3. Alisha Oropallo, MD, FACS, FSVS, FAPWCA

Dr. Oropallo is a Professor at the Zucker School of Medicine at Hofstra/Northwell and Director of the Comprehensive Wound Healing Center at Northwell Health. She is board-certified in General and Vascular Surgery and is a Fellow of the American College of Surgeons. ​LinkedIn+4ResearchGate+4CITI Program+4woundcarecc.org

• Northwell Health Profile

4. Martha R. Kelso, RN, CHWS, HBOT

Ms. Kelso is the CEO of Wound Care Plus, LLC, one of the nation’s largest mobile wound care providers. She is recognized as a visionary in mobile medicine and is a published author and clinical editor for multiple peer-reviewed journals. ​hmpglobalevents.com+3Log in or sign up to view+3LinkedIn+3hmpglobalevents.com+3pawsic.org+3LinkedIn+3

• PAWSIC Bio

5. Jeffrey A. Niezgoda, MD, FACHM, MAPWCA, CHWS

Dr. Niezgoda is the President and Chief Medical Officer of WebCME and serves as the CMO for Kent Imaging. He is the Past President of the American Professional Wound Care Association and the American College of Hyperbaric Medicine. ​LinkedIn+8ipawssummit.org+8kentimaging.com+8

• Kent Imaging Leadership Profile

6. Naz Wahab, MD, FAAFP, FAPWCA

Dr. Wahab is a board-certified family physician and wound care specialist. She serves as the Medical Director for the Mountain View Outpatient Wound Care and Hyperbaric Center and is an active member of several wound care organizations. ​reddressmedical.com+4Medical News Today+4aawconline.memberclicks.net+4aawconline.memberclicks.net+3reddressmedical.com+3campswoundcaresummit.com+3

• RedDress Medical Profile

7. Julie L. De Jong

Information on Julie L. De Jong’s professional background in wound care is limited in the provided sources. Further details may be available through institutional affiliations or publications.​

8. Brandon Hubbs

Mr. Hubbs is an experienced Cardiovascular Administrator and Nurse, affiliated with FirstHealth of the Carolinas. ​LinkedIn

• LinkedIn Profile

9. R. Allyn Forsyth

Dr. Forsyth has contributed to research on wound care, including studies on the cost of chronic wound care for Medicare beneficiaries. ​ResearchGate

10. Gregory A. Magee, MD

Dr. Magee is an Associate Professor of Clinical Surgery at the Keck School of Medicine of USC. He completed fellowships in surgical critical care and trauma surgery at USC and in vascular surgery at the University of Colorado Denver. ​Healthgrades+4Keck School of Medicine of USC+4SC CTSI Profiles+4Keck Medicine of USC

• Keck Medicine Profile

11. Paul Steel

Specific information about Paul Steel’s professional background in wound care is not readily available in the provided sources. Further details may be found through academic publications or institutional affiliations.​

12. Benjamin G. Cohen, DPM

Dr. Cohen is a Podiatric Medicine specialist and Podiatric Surgeon based in Aiken, South Carolina. He is recognized as an advanced expert in his field. ​Medifind+1Maggie Online Library+1

• MediFind Profile

13. William V. Padula, PhD

Dr. Padula is an Assistant Professor of Pharmaceutical & Health Economics at the USC Mann School of Pharmacy and a Fellow at the USC Leonard D. Schaeffer Center for Health Policy & Economics. His research focuses on cost-effectiveness analysis and healthcare delivery, particularly regarding pressure injury prevention. ​USC Schaeffer+2USC Mann School of Pharmacy+2SC CTSI Profiles+2NCBI+3USC Schaeffer+3ResearchGate+3

• USC Schaeffer Center Profile

One of the greatest challenges in wound care is the widespread lack of understanding and training around debridement, a crucial step in healing chronic wounds by removing necrotic tissue, usually through sharp debridement. Many caregivers hesitate due to fear of causing harm or discomfort, underscoring the need for hands-on mentorship rather than relying solely on videos or reading. The extent to which nurses and medical assistants can safely debride varies based on experience, availability of doctors, anesthesia use, and anatomical knowledge. In practice, nurses often manage routine outpatient debridements, while deeper procedures are left to surgeons. Debridement is generally safe if limited to dead tissue, though bleeding must be controlled properly, and anatomical landmarks—such as major vessels, nerves, and joint capsules—must be respected to avoid serious complications. Patient pain management is important, with oral analgesics like paracetamol and codeine given in advance, except in patients with severe neuropathy who may not feel pain … read more

About Wounds Africa:
WoundsAfrica is a non-profit educational platform dedicated to enhancing wound care across the African continent, particularly in regions with limited resources. The website offers practical, experience-based guidance tailored for healthcare professionals such as nurses, medical assistants, podiatrists, and doctors. Recognizing the vast disparities in wound care access—from advanced urban clinics to remote rural settings—the platform provides adaptable strategies for diverse clinical environments. The editorial team comprises seasoned experts: Isabella Stokka Landmark, a certified nurse practitioner and tissue viability nurse involved in research and quality control; Anne Catherine Skaar, a senior consultant anesthesiologist with extensive experience in surgical and burn care; and Bodo Günther, a senior orthopedic consultant and assistant professor with over two decades in advanced wound management. Together, they emphasize the importance of practical skills, ethical considerations, and community engagement to improve wound care outcomes throughout Africa. ​

From LEKHA MUTYALA
Summary:
Revolutionizing Diabetic Foot Ulcer Care with 3D Technology
Diabetic foot ulcers (DFUs) affect 1 in 4 individuals with diabetes and contribute significantly to healthcare costs and lower limb amputations worldwide. Traditional treatments—like wound debridement, glycemic control, and surgical interventions—offer limited scalability in the face of rising diabetes prevalence. Fortunately, innovative technologies are reshaping the future of DFU management. 3D-printed antibiotic bandages from Queen’s University promise rapid healing and reduced clinical burden. Meanwhile, Indian researchers have developed custom, pressure-sensitive 3D-printed footwear to enhance balance and recovery. In surgical care, 3D-bioprinted adipose tissue has successfully prevented amputations in high-risk patients. These advancements highlight how personalized, tech-driven solutions can reduce complications, improve outcomes, and lower healthcare costs for diabetic patients. Full article

————

Lekha Mutyala is a podiatry student at Kent State University College of Podiatric Medicine (KSUCPM). In 2024, she won the 38th Annual American Podiatric Medical Writers Association (APMWA) Student Writing Competition for her paper titled “Advancements in Technology and Innovative Approaches in Diabetic Foot Ulcer Management.” This achievement earned her a $1,000 honorarium from an endowment by Dr. and Mrs. Steven Berlin to the APMA Educational Foundation .​

Additionally, Mutyala was recognized as a 2024–2025 APMA Educational Foundation scholarship recipient, highlighting her academic excellence and commitment to the field of podiatric medicine

Thanoon Thabet MSN, RN, WOCN, WTA-C

Wound healing is a multifaceted and complex biological process involving various stages including hemostasis, inflammation, and tissue remodeling, leading to the restoration of damaged tissue and skin.1 In recent years, the evolution of science has seen the emergence of specialized dressings, such as bioactive dressings, which may help to speed the wound healing processes and reduce complications.2 Such advancements in medical knowledge and the growing demand for individualized, data-driven approaches are gradually challenging traditional wound care strategies. Consequently, healthcare professionals are incorporating technologies that increase the personalization and precision of wound care to better tailor and monitor treatments. Digital twins are one of these recent technologies that could have great potential in the wound care field. This technology integrates data from patient history, sensors, and medical imaging to develop real-time virtual representations of patients’ wounds.3 Digital twin technology enables healthcare providers …. read more

chronic wound‐care competence in student nurses and podiatrists

The purpose of this study was to describe the level of chronic wound‐care competence among graduating student nurses and student podiatrists in comparison with that of professionals and to develop and test a new instrument (the C/WoundComp) that assesses both theoretical and practical competence in chronic wound care as well as attitudes towards wound care. The data (N = 135) were collected in 2019 from four groups (1): graduating student nurses (n = 44) (2); graduating student podiatrists (n = 28) (3); registered nurses (n = 54); and (4) podiatrists (n = 9). The data were analysed using statistical analysis. According to the results, the students’ total mean competence score was 62%. Their mean score for theoretical competence was 67%, and for practical competence, it was 52%. The students’ competence level was statistically significantly lower than that of the professionals (P < .0001), but the students showed a positive attitude towards chronic wound care. The instrument demonstrated preliminary validity and reliability, but this warrants further testing. This study provides new knowledge about student nurses’ and …. full article

———————

Summary:

This study aimed to develop and test a new assessment tool—called the C/WoundComp instrument—to evaluate both theoretical and practical competence in chronic wound care among student nurses and podiatrists. It also examined their attitudes toward chronic wound care.

Design & Participants: The study used a descriptive, comparative, and methodological approach with 135 participants:

• 44 graduating student nurses

• 28 graduating student podiatrists

• 54 registered nurses

• 9 practicing podiatrists

Key Findings:

• Students had an average competence score of 62% overall:

  • 67% in theoretical knowledge

  • 52% in practical skills

• Professionals scored significantly higher than students.

• Students showed positive attitudes toward chronic wound care despite limited competence.

• The C/WoundComp instrument showed initial reliability and validity for assessing wound-care competence.

Conclusion: Graduating students lack sufficient theoretical and practical knowledge in chronic wound care, highlighting the need to strengthen wound-care education. The C/WoundComp tool could help evaluate and improve competence in this critical area of healthcare.

The authors:

• Emilia Kielo-Viljamaa, PhD, RN: Dr. Kielo-Viljamaa is a Senior Lecturer at Novia University of Applied Sciences, Faculty of Health and Welfare, in Vaasa, Finland. She also serves as a Postdoctoral Researcher at the University of Turku’s Department of Nursing Science. Her research focuses on nursing education and wound care competence. ​ResearchGate

• Riitta Suhonen, PhD, RN: Dr. Suhonen is affiliated with the Department of Nursing Science at the University of Turku, Turku University Hospital, and the Welfare Division of the City of Turku in Finland. She has an extensive background in nursing science and education. ​PubMed

• Maarit Ahtiala: Associated with Turku University Hospital in Finland, contributing to research in nursing and healthcare. ​PubMed

• Terhi Kolari: Affiliated with the Department of Biostatistics at the University of Turku, focusing on statistical analysis in medical research. ​PubMed

• Jouko Katajisto: Part of the Department of Mathematics and Statistics at the University of Turku, specializing in statistical methodologies. ​PubMed

• Leena Salminen, PhD, RN: Connected with the Department of Nursing Science at the University of Turku, with research interests in nursing education and professional competence. ​PubMed+1ResearchGate+1

• Minna Stolt, PhD, RN: Also from the Department of Nursing Science at the University of Turku, Dr. Stolt’s research includes nursing education and wound care. ​PubMed

​

Society of Tissue Viability Conference 2025
Solving skin and wound challenges together

30 April – 01 May 2025
LIFE Centre, Wapping Road, Bradford BD3 0EQ

Want to attend?
We are delighted to offer several FREE conference registrations (travel / accommodation bursaries are ‘sold out’) to attend our conference. Link below to find out more and apply now.

Call for abstracts
Are you doing some great work in research? Do you have a case study or product evaluation that you would like to present? Then consider submitting to #SoTV2025! The call for abstracts is now open! Find out more below. Closing 28 February, 2025. Submissions now closed. Thank you to everyone that has submitted – we will notify you of the results soon

Get in touch
If you have any questions, email hello@societyoftissueviability.org

A wound heals by progression through various stages of inflammation, granulation tissue synthesis, collagen deposition and maturation, and epithelization.¹ The majority of acute wounds follow this organized pattern to achieve structural and functional stability. However, some acute wounds with large raw areas progress into chronic wounds refractory to conventional treatments. The presence of bacteria in significant numbers is one important reason a wound may not proceed through the healing trajectory …. full article

Speaker:

A Multimethod Study

Diabetes-related lower extremity amputations (LEAs) are among the most devastating complications of diabetes, profoundly impacting physical, psychological, and social well-being. The Diabetes-Related Extremity Amputation Depression and Distress (DREADD) study examines the emotional and psychological consequences of amputation in diabetic individuals, employing a multimethod approach to capture the full spectrum of patient experiences.

The Psychological Toll of Amputation

Individuals who undergo amputations due to diabetes-related complications, such as diabetic foot ulcers and peripheral artery disease (PAD), often experience profound emotional distress. Depression, anxiety, and post-traumatic stress are common, exacerbated by a loss of mobility, independence, and altered self-identity. Many struggle with feelings of grief, shame, and social isolation, impacting their overall quality of life and mental health.

A Multimethod Approach

The DREADD study employs both qualitative and quantitative research methods to explore these psychological impacts. Surveys and standardized depression scales, such as the Patient Health Questionnaire-9 (PHQ-9), are used to measure depression severity, while structured interviews provide insights into personal struggles, coping mechanisms, and unmet psychological needs. Additionally, biometric data, including heart rate variability and cortisol levels, offer physiological indicators of chronic stress and emotional dysregulation.

Findings and Implications for Care

Preliminary findings suggest that nearly half of patients experience moderate to severe depression post-amputation, with many lacking adequate mental health support. Factors such as poor social support, financial strain, and preexisting mental health conditions contribute to worse outcomes. The study underscores the need for integrated care models that address both physical and psychological rehabilitation, including peer support groups, counseling services, and cognitive behavioral therapy (CBT) to improve patient adaptation and emotional resilience.

By highlighting the critical intersection between diabetes, amputation, and mental health, the DREADD study aims to reshape post-amputation care, advocating for holistic interventions that go beyond wound healing to address the profound psychological distress faced by affected individuals.

by Claire Kowalick, University of Texas Health Science Center at San Antonio

Texas has one of the highest rates of diabetes in the country, with more than 2.7 million Texans diagnosed with the condition. About one in six people in San Antonio have type 2 diabetes, and a third of residents are prediabetic, according to the American Diabetes Association.

Type 2 diabetes is a chronic condition in which the body cannot produce enough insulin or use insulin properly and, if left uncontrolled, can lead to high blood sugar, heart disease and kidney failure. It also predisposes people to foot ulcers, of which almost 50% become infected, subsequently leading to hospitalization and potentially amputation of part of the foot or a lower limb … full article

related:

Texas has one of the highest rates of diabetes in the country, with more than 2.7 million Texans diagnosed with the condition. This epidemic has significant implications for healthcare systems, particularly in the management of complications like diabetic foot ulcers (DFUs). In San Antonio, where approximately one in six residents has type 2 diabetes and a third of the population is prediabetic, the risk of developing DFUs is alarmingly high.

Diabetic foot ulcers result from a combination of neuropathy, poor circulation, and impaired immune response, all of which are common in individuals with long-standing diabetes. Without proper intervention, these ulcers can progress to severe infections, leading to hospitalizations, amputations, and increased mortality rates. Given the high prevalence of diabetes in Texas, hospitals and wound care centers face mounting challenges in treating and preventing these wounds effectively.

The economic burden of DFUs is also substantial. Studies indicate that treating a single DFU can cost tens of thousands of dollars, with the total cost of diabetic foot care in the U.S. exceeding billions annually. In areas like San Antonio, where diabetes rates are disproportionately high, local healthcare facilities must prioritize specialized wound care services, early detection, and preventive measures such as total contact casting (TCC) to offload pressure from wounds and enhance healing.

Community-wide initiatives are essential to combat this growing crisis. Increasing awareness about proper foot care, expanding access to podiatric and wound care specialists, and implementing preventive strategies—such as routine screenings for neuropathy and peripheral artery disease (PAD)—can significantly reduce the incidence and severity of DFUs. Additionally, addressing social determinants of health, such as limited access to quality healthcare, lower socioeconomic status, and dietary challenges, is crucial in mitigating the long-term consequences of diabetes-related foot complications.

As Texas continues to grapple with rising diabetes rates, proactive intervention and innovative wound care solutions will be key in preventing DFUs and improving patient outcomes.

Background. Martorell hypertensive ischemic leg ulcer (HYTILU) is a chronic, hard-to-heal wound linked to hypertension. This study explores nanofat grafting as a regenerative alternative to traditional skin grafting for improved healing and patient outcomes. Objective. To explore the efficacy of nanofat grafting in the management of HYTILU and compare it with skin grafting. Materials and Methods. This was a retrospective single-center pilot study involving 23 patients with HYTILU treated with adipose-derived stromal cells (adipose-derived stromal cells/nanofat). The primary outcomes were ulcer healing rate, pain reduction, and improvements in quality of life, as measured by SCAR-Q (a scar quality of life questionnaire) and the Vancouver Scar Scale, over a period of 6 months posttreatment. Results. This study revealed a significant decrease in ulcer size from an initial mean of 39.69 cm² to complete healing, with an average healing time of 4.65 months. The mean visual analog scale pain scores significantly decreased from an initial score of 5.87 to 0.39 at 3 months …. read more

Kathleen D. Schaum, MS

Medicare coverage for distinct types of wounds/ulcers has received attention for many years. Because the theme of this issue of Advances in Skin & Wound Care is pressure injuries (PIs), this article reviews whether Medicare covers certain technologies and procedures for PIs.

DEBRIDEMENT

Most Medicare Administrative Contractors (MACs) have a Local Coverage Determination (LCD) and Local Coverage Article (LCA) that address the coverage guidelines for debridement of all types of wounds/ulcers, including PIs. Some MACs have a separate debridement LCD/LCA, whereas others include debridement coverage guidelines within their LCD/LCA related to wound care. Readers should check their MAC’s LCDs, which do not limit debridement to distinct wound types. However, their LCDs/LCAs have similar coverage guidelines that include, but are not limited to, documentation of:

• History and physical examination with an initial wound description, location, measurements, and response to prior treatment (if applicable).
• Identification of wound location, size, depth, and stage (supported by a drawing or photograph of the wound).
• Clinical documentation of diagnosis or symptoms to justify services.
• Current progress notes including measurable signs of healing as well as causes of delayed wound healing or modifications to the treatment plan.
• Documentation of the wound’s characteristics (e.g., dimensions, necrotic tissue presence, tissue removed, degree of epithelialization) before and after debridement.
• Operative note or procedure note for debridement services, including descriptions of tissue debrided, wound measurements, and pre-/post-debridement wound assessments.
• Plan of care containing treatment goals and physician follow-up.read full article

Kathleen D. Schaum, MS, is a healthcare reimbursement expert specializing in wound care, durable medical equipment (DME), and Medicare coverage policies. She is the president and founder of Kathleen D. Schaum & Associates, a consulting firm focused on payment strategies for healthcare providers and manufacturers. Schaum is a frequent author and speaker on reimbursement-related topics in wound care and medical technology.

Johns Hopkins University has announced plans to eliminate over 2,200 jobs following the Trump administration’s decision to cut $800 million in grants previously allocated by the U.S. Agency for International Development (USAID). This reduction represents the largest layoff in the university’s history, affecting 247 positions within the United States and 1,975 positions across 44 countries.

The job cuts will impact several key divisions of the university, including the Bloomberg School of Public Health, the School of Medicine, and the affiliated nonprofit organization Jhpiego, which focuses on international health initiatives. The university expressed deep concern over the funding termination, stating that it forces them to wind down critical work both domestically and internationally.

This development is part of a broader trend affecting higher education institutions across the United States. Several universities, including Harvard, the Massachusetts Institute of Technology, and the University of California, San Diego, have implemented hiring freezes and other cost-saving measures in response to federal funding uncertainties. These financial strains threaten the academic and research integrity of these institutions and pose risks to job growth in higher education.

The reduction in USAID funding is expected to have significant implications for global health initiatives, particularly those targeting infectious diseases and women’s health in low-income countries. Johns Hopkins University and other research institutions anticipate further financial challenges and have initiated legal actions against the proposed budget reductions.

As the largest private employer in Maryland and Baltimore, Johns Hopkins University’s decision to cut over 2,000 jobs underscores the real-world impact of federal funding policies on employment and public health research.

Alton R. Johnson Jr., DPM, DABPM, FACPM, FASPS, CWSP
John Steinberg, DPM, FACFAS

In this insightful episode, Dr. Alton Johnson, Dr. John Steinberg, and host Brian discuss the often-overlooked phase of wound care: life after healing. The conversation shifts from the traditional focus on simply closing wounds to a broader perspective that emphasizes function, long-term remission, and patient education.

Dr. Johnson shares his journey as a young physician who initially believed healing was the final step, only to realize that patients frequently return due to recurring wounds. He highlights the importance of educating patients on easing back into daily activities and managing their healed wounds like a condition in remission.

Dr. Steinberg builds on this by emphasizing function over limb salvage, noting that saving a limb without restoring mobility can leave patients unable to regain independence. He recalls advice from his colleague, Dr. Chris Attinger, who stressed that preventing wounds from returning is just as crucial as healing them.

The discussion underscores the need for early planning in the healing process, ensuring patients have the right prosthetics, orthotics, and footwear in place before their wounds fully close. By shifting the focus from simply healing wounds to optimizing long-term mobility and quality of life, this episode offers valuable insights for clinicians, caregivers, and patients alike.

Listen

This event will be held at 7:30pm, 26th February 2025.

Presented by Paulo Ramos, RN, (Nurse Specialist at ULS Póvoa de Varzim / Vila do Conde, USF Corino de Andrade, Portugal. Certified wound care educator. Board Member of the Portuguese Wound Care Association and a EWMA Council Member. Member of the EWMA Working Groups of AMS and Compression Therapy. Chair of EWMA Education Comittee).

Register interest

by Caroline Fife, M.D. | Feb 19, 2025

A taxonomy code is a unique 10-character identifier that specifies a practitioner’s (physician or nurse practitioner) classification and specialization. This code is required when applying for a National Provider Identifier (NPI), which is necessary for billing Medicare. NPI applications are processed through the National Plan & Provider Enumeration System (NPPES). Clinicians are expected to select the taxonomy code that best represents their provider type, classification, or specialization. However, I am not aware of any regulations mandating that a practitioner be board-certified in the specialty associated with their chosen taxonomy code.
https://carolinefifemd.com/2025/02/19/new-taxonomy-codes-for-wound-care-practitioners/

Recognizing Excellence in Wound Care Research and Practice

The Journal of Wound Care (JWC) Awards 2025 took place on Friday, 14th February 2025, at the prestigious Imperial War Museum in London. This annual event celebrates excellence in research, innovative practices, and outstanding contributions across the wound care community.

This year’s winners and finalists represent the dedication and expertise driving advancements in wound care, from pioneering clinical interventions to transformative research and education. Their work continues to push the boundaries of patient care, setting new standards for the field.

Congratulations to all those recognized for their achievements!

For a full list of winners and highlights from the event, visit the JWC Awards website.

Frank and Lizzie sit down with Mark Overcash, RN, WCSP, a seasoned wound care specialist with over 25 years of experience and the National Sales Manager at MPM Medical. In this insightful conversation, Mark shares the latest industry trends, key findings from professional surveys, and the increasing demand for multifunctional, cost-effective wound dressings.

MPM Medical, a leader in advanced wound care since 1992, has consistently prioritized feedback from healthcare professionals to develop innovative solutions. Their newest product, TriSAP, is a silicone-based, silver-infused, super-absorbent dressing designed to tackle exudate management, infection control, and reimbursement challenges.

Join us for an in-depth discussion on how TriSAP is shaping the future of wound care and revolutionizing patient treatment!

https://www.hmpgloballearningnetwork.com/site/wounds/videos/frank-lizzie-show-episode-27-multifunctional-dressings-future-doing-more-less

Mark Overcash, RN, CWSP, is a seasoned wound care specialist with over 25 years of experience. He began his nursing career in 1997 and transitioned to medical sales focusing on wound care in 2000. In 2023, Mark joined MPM Medical, and within a year, he was promoted to National Sales Manager.

He has been instrumental in promoting MPM Medical’s latest dressing, TriSAP, which addresses exudate management, infection control, and supports reimbursement needs.

Mark actively engages with healthcare professionals at industry events, such as the Desert Foot conference, to share advanced solutions for diabetic and venous stasis ulcers.

ANAHEIM, Calif., July 5, 2023 /PRNewswire/ — Histologics LLC attended “WOCNext” in Las Vegas last June 4-6th to exhibit its novel debridement and wound biopsy fabric-curettage devices including for the first time, the SoftBiopsy®+D device. Over 1M cases by clinicians used Kylon® devices for colposcopic biopsy and curettage in the USA, in nearly every clinical setting www.histologics.com. The hooked medical (Kylon®) fabric tipped brushes gently remove and can trap tissue for biopsy for histology or microbiology. The debridement may be performed at a lighter “hygiene” level, extending all the way to “excisional” surgical methods when the brush array converts to micro-curettes if the fabric is pressed firmly and wiped or twisted into tissue.

Kylon® Fabric Debridement and Biopsy : Video Simulation

The cause of some wounds not to heal includes biofilm, and the Kylon® fabric devices can be used to obtain true tangential biopsy samples from the debrided wound base for lab testing.  This is commonly done with the SoftBiopsy® product, solely used for biopsy that is sent to a laboratory. Histologics recently released SoftBiopsy®+D, a more versatile and durable version for clinicians, that can sustain longer procedure time for wound debridement as well as biopsy.

We have previously demonstrated the value of our Soft K-Rette® device to debride and sample crevice wounds, and Soft K-Cot® deployed on the finger for “Compassionate Debridement at Your Fingertips®”.

The scope of practice of most physicians and nurse clinicians vary from basic wound care to the most advanced surgical procedures where necrotic wound tissue must be mechanically or surgically removed.  Advanced and basic wound care providers include many specialties in health care and procedures occur in clinics, hospitals, homes, facilities and other settings. Some providers that shy away from regular debridement (necessary to heal wounds) due to the invasive nature of the scalpel and sharp curette would be willing to clean wounds using the gentle  Kylon® devices.

Please visit our wound care website to request free samples at www.histologicwc.com,  or contact Lily Ramos at histologicswc@gmail.com, Toll Free:  888-235-2275.

SOURCE Histologics LLC

Former Healogics CEO Brings Deep Wound Care Industry Experience to MolecuLight’s
Rapidly Growing Business

TORONTO, July 6, 2023 /PRNewswire/ – MolecuLight Inc., the leader in point-of-care fluorescence imaging that locates and detects elevated, pathogenic bacterial loads in and around wounds, is pleased to announce the appointment of David Bassin to its Board of Directors as an Independent Board Member.

David Bassin brings a wealth of expertise and experience in the healthcare industry, particularly in the field of wound care. As the founder of GIO Advisory LLC, he has provided invaluable advisory services to numerous companies and private equity firms based on his extensive background in healthcare, spanning pharmaceutical/device, payer, and provider services. Most recently, Bassin served as the CEO of Healogics, the foremost provider of wound care services in the US, operating over 630 wound care centers and 300 providers. During his tenure, he successfully restructured and refocused the business, resulting in strong earnings growth prior to his transition into advisory services. Prior to his role as CEO, Bassin served as the CFO of Healogics, contributing to the company’s financial growth and success. Bassin’s impressive career also includes significant roles in other healthcare organizations. He served as the CFO of eviCore Healthcare, Inc., where he oversaw multiple dividend recapitalizations and facilitated a merger with the company’s largest competitor, leading to the creation of a company with over 3,000 employees. Additionally, Bassin held the position of CFO at InVentiv Health, Inc., a provider of services to pharmaceutical companies, where he successfully managed a high-growth company and orchestrated a go-private transaction valued at over $1 billion and delivered a significant premium to its shareholders.

“We are thrilled to welcome David Bassin to the MolecuLight Board of Directors,” said Anil Amlani, CEO of MolecuLight. “His extensive experience in optimizing and scaling organizations across the healthcare industry, particularly in wound care, will be invaluable to MolecuLight as we continue to expand our global presence. Our MolecuLight devices have already become indispensable tools in wound assessment and real-time decision-making for thousands of clinicians worldwide. David’s expertise will greatly support our mission to meet the increasing global demand for our innovative wound care diagnostics and establish them as the gold standard in the field.”

David Bassin expressed his excitement about joining MolecuLight’s Board of Directors, stating, “There are over 6.5 million patients living with wounds.  As an industry, we need to continue to develop new solutions that improve wound care treatment effectiveness and efficiency.  With a global drive to improve outcomes, reduce costs, and minimize antibiotic usage, MolecuLight’s point-of-care devices have demonstrated their ability to effectively address these critical clinical needs. I am deeply impressed by the organization, the technology’s alignment with market demands, and the significant market traction they have achieved. I am eager to contribute to their growth and help them achieve their ambitious goals.”

MolecuLight’s groundbreaking i:X® and DX™ imaging devices are the only FDA-cleared and CE and Health Canada approved devices for the real-time detection of elevated bacterial burden in wounds. Supported by over 80 peer-reviewed publications involving 2,600 patients, these devices are widely utilized by leading wound care facilities worldwide.

MolecuLight Inc. is a privately-owned medical imaging company that has developed and is commercializing its proprietary fluorescent imaging platform technology in multiple clinical markets. MolecuLight’s commercial devices, which include the MolecuLight i:X® and DX™ fluorescence imaging systems and their accessories, are point-of-care handheld imaging devices for the real-time detection and localization of bacterial load in wounds and digital wound measurement. MolecuLight procedures performed in the United States benefit from an available reimbursement pathway which includes two CPT® codes for physician work to perform “fluorescence imaging for bacterial presence, location, and load” and facility payment for Hospital Outpatient Department (HOPD) and Ambulatory Surgical Center (ASC) settings through an Ambulatory Payment Classification (APC) assignment. The company is also commercializing its unique fluorescence imaging platform technology for other global markets with relevant unmet needs in food safety, consumer cosmetics and other key industrial markets.

For more information, contact:

Rob Sandler 
Chief Marketing Officer
MolecuLight Inc.
T. +1.647.362.4684
rsandler@moleculight.com
www.moleculight.com

Image:

• Download: https://moleculight.box.com/s/91awddbrynrybjwkeyyabgcbz8fxk9xh

SOURCE MolecuLight

Led by Susa Ventures and Sozo Ventures, the funding will be used to transform the $45B wound and ostomy care industry by bringing on-demand experts to more patients and providers in need via telehealth and in-person visits

The Wound Company, a multi-channel on-demand wound and ostomy care delivery company that improves patient outcomes, today announced its launch from stealth with $4.25M in seed funding from Susa Ventures and Sozo Ventures. The funding will be used to expand the company’s national footprint, hire top talent, and to continue improving health outcomes in the most cost-effective way possible while bringing dignity to the over 13 million people in need of improved wound and ostomy care.

Why Wound Care Matters

The US is experiencing an amputation epidemic due to diabetic foot ulcers and other serious wounds. Despite medical advancements, Americans are amputating double the number of limbs today than during the Civil War. About 50% of lower extremity amputations would have been preventable if patients with type 2 diabetes and foot ulcers had access to better healthcare. This issue is one of the problems The Wound Company is solving for.

Often providers need more wound care expertise or, due to understaffing, don’t have time to offer comprehensive care continuously, leaving patients to figure it out on their own. This leads to wound care patients returning to the hospital due to improper wound care. But it can be prevented.

“The wound and ostomy care industry is broken,” said Nima Ahmadi, founder and CEO of The Wound Company. “It’s operating in the fee-for-service world, which pushes expensive procedures and products that help the bottom line, but don’t impact outcomes for the patient. We’re paid to heal wounds with continuous care and, in doing so, save money for health plans and at-risk providers.”

Enter The Wound Company

The Wound Company aims to fix the broken space of wound and ostomy care by using predictive analytics and multi-channel communications to deliver the right wound and ostomy care to the right patient in the right channel at the right time. The tech connects patients and providers to wound and ostomy experts virtually or via in-person visits to ensure they have top-tier care.

“The Wound Company’s innovative technologies have the potential to save health plans billions of dollars and transform the patient experience,” says Susa Ventures Investor Derick En’Wezoh. “With a dedicated team of highly experienced experts, a strong vision, and a passion for improving healthcare outcomes, this tech will save lives.”

The platform also offers clinical reporting, customer data integration, and workflow automation to make care delivery as painless as possible for providers.

While in stealth, The Wound Company has already partnered with health plans, health systems, home care providers, hospice providers, and patients, with significant results to date:

• A potential 15-20% reduction in the total cost of care for wound and ostomy patients for payers
• Up to 50% savings on supplies per patient for home and hospice care providers
• 60% of patients demonstrated progressive healing week after week
• 90% of Stage I/II pressure ulcers resolved without advancing to a higher stage
• 100% of ostomy patients have a predictable pouching system and reduced chance of ER visits or readmissions

“Our blend of virtual and in-person services provided by passionate experts in wound care helps people heal quickly, safely, and with the dignity they deserve while helping to alleviate the pressure on overworked healthcare professionals,” said Chief Medical Officer Sanford Roberts.

The Wound Company is open to partnerships with health plans, at-risk providers, home health providers, and hospice care providers. For more information, visit www.thewound.co.

About The Wound Company

The Wound Company is a Minneapolis-based technology company dedicated to advancing wound and ostomy care. The company uses proprietary technology to connect providers with experienced and certified wound care specialists who can care for patients virtually or via in-person visits. The Wound Company partners with health plans, home care companies, and providers to bring dignity to patients with wounds and ostomies while increasing positive patient outcomes.

This article was originally published here

David G. Armstrong, DPM, PhD, is an internationally recognized leader in the field of podiatric surgery, diabetic foot, limb preservation, and wound healing.

DALLAS, TX, USA, June 12, 2023/EINPresswire.com/ — Venturis Therapeutics, Inc. (“VT” or the “Company”) announces that David G Armstrong, DPM MD PhD will assume the role of senior academic advisor for the surgeon board. This agreement was consummated following a review of the Company’s scientific and commercial opportunities.

Armstrong is the foremost expert in diabetic limb preservation and is recognized worldwide with a huge following through his prodigious authorship and lectures on diabetic limb salvage. This affiliation will further enhance the diabetic wound program and clinical research trials being undertaken by VT, and will improve the visibility of the Company dramatically among all those in the greater biotech wound healing community.

ABOUT VENTURIS THERAPEUTICS
Venturis Therapeutics, Inc. is a biopharmaceutical company developing protein drug candidates to address diseases such as severe coronary heart disease, diabetic wounds, peripheral artery disease, erectile dysfunction, stroke, and spinal disk disease. The active pharmaceutical ingredient (“API”) in our drug candidates is FGF-1, a human protein that stimulates the growth of new blood vessels, thereby increasing the blood supply to ischemic organs and tissues.

FORWARD LOOKING STATEMENTS
This news release contains forward-looking statements that involve risks and uncertainties. Actual results and outcomes may differ materially from those discussed or anticipated. For example, statements regarding expectations for new research, progress with clinical trials or future business initiatives are forward looking statements. Factors that might affect actual outcomes include, but are not limited to, FDA approval of VT drug candidates, market acceptance of VT products by customers, new developments in the industry, future revenues, future expenses, future margins, cash usage, and financial performance. Additionally, until VT is cash flow positive from operations, the Company is dependent upon raising capital to fund its operations and meet its obligations as they come due. There can be no assurance that VT will be able to raise the necessary capital when needed.

Amy Gordon
Venturis Therapeutics Inc
+1 972-904-2029
email us here

Dr. David G Armstrong The 18th Malvern Diabetic Foot Conference Future of Wound Treatment

NEXA NPWT System Launched in the USA

OCEANSIDE, Calif., June 7, 2023 /PRNewswire/ — AOTI Inc, the global leader in multi-modality topical wound oxygen, announced exciting news from ongoing WOCNext conference in Las Vegas, Nevada, where their game changing NEXA Negative Pressure Wound Therapy (NPWT) system made its official USA debut.

The unique NEXA NPWT system is an incredibly flexible platform that is simple to use, silent, portable and affordable. NEXA seamlessly combines the simplicity of disposable NPWT with the performance features of more traditional durable NPWT technology platforms.

Dr. Mike Griffiths, CEO and President of AOTI commented; “Releasing the innovative NEXA NPWT platform in the USA is a major milestone for the company that will allow clinicians, payers, and patients alike to experience much improved performance at significantly lower cost. With NEXA, we have reimagined how NPWT should function.

Its addition to our portfolio only further enhances our mission of helping all people with chronic conditions get back to living their lives to the fullest.”

AOTI’s unique NEXA NPWT and Topical Wound Oxygen (TWO2) therapy are unlike any other treatment approaches. NEXA provided unrivaled flexibility and performance in a portable NPWT system. TWO2 is the only device that provides a multimodality treatment, combining higher pressure oxygen delivery with non-contact cyclical compression and humidity, in a therapeutic applied by the patient at home. This patented approach has been demonstrated in numerous Randomized Controlled Trial (RCT) and Real World Evidence (RWE) studies to not only heal chronic wounds at a far higher rate, but perhaps more importantly, keep them closed longer term, thereby reducing unnecessary hospitalizations and amputations.^{1, 2}

¹ Multinational, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy of Cyclical Topical Wound Oxygen (TWO2) Therapy in the Treatment of Chronic Diabetic Foot Ulcers; The TWO2 Study. Robert G. Frykberg et al, Diabetics Care 2020; 43:616-624. https://doi.org/10.2337/dc19-0476.

² Reduced Hospitalizations and Amputations in Patients with Diabetic Foot Ulcers Treated with Cyclical Pressurized Topical Wound Oxygen Therapy: Real-World Outcomes; Jessica Izhakoff Yellin, et al; Advances in Wound Care 2022; http://doi.org/10.1089/wound.2021.0118

About AOTI

AOTI is a privately-owned company based in Oceanside, California USA and Galway, Ireland that provides innovative solutions to resolve severe and chronic wounds worldwide. Our mission is to help all people with chronic conditions get back to living their lives to the fullest. We do this by enhancing access to care, improving quality of life and advancing health equity. 
Our products reduce healthcare costs and improve the quality of life for patients with these debilitating conditions. Our patented Topical Wound Oxygen (TWO2) at home therapy is clinically proven to deliver Sustained Wound Healing that reduces both Amputations and Hospitalizations, So Life Can Get Back to Normal.

For more information see: www.aotinc.net

Contact:
Dr. Mike Griffiths
CEO & President
360322@email4pr.com
(760) 672 1920

SOURCE AOTI Inc.

BOULDER, CO / ACCESSWIRE / June 8, 2023 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn^® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, dermatology, and eye, oral and nasal care, today announced a new application for intraoperative pulse lavage irrigation treatment, which can replace commonly used IV bags in a variety of surgical procedures.

Sonoma developed this new application of its wound care technology in response to an unmet need for a non-toxic irrigation solution that can prevent infection and improve healing time. The intraoperative pulse lavage container is designed to be used in combination with a pulse lavage irrigation device, or flush gun, for abdominal, laparoscopic, orthopedic, and periprosthetic procedures. This product replaces commonly used non-antimicrobial saline and aggressive rinsing solutions with safe and effective Microcyn^® Technology. Microcyn^® Technology assists in the reduction of microorganisms, is non-toxic, and has regenerative properties, making it critical in preventing infection and promoting wound healing. Sonoma’s pulse lavage container is also cost competitive with IV bags, the current standard of care.

Sonoma developed the intraoperative pulse lavage irrigation treatment in close collaboration with the medical community and Sonoma’s existing distribution partners in Europe and expects this new application will be met with wide acceptance. Sonoma is now accepting orders for the pulse lavage irrigation treatment solution, which is expected to be ready for commercial use in Europe in September 2023. Sonoma anticipates commercial launch in the U.S. in 2024.

“Sonoma continues to lead in the innovation of products that improve outcomes for people with wounds or injuries or who are needing surgery. We continue to see increased demand for our wound care products in Europe, and we are excited to expand our offerings to include this next generation irrigation solution to help people heal faster following surgery,” said Amy Trombly, CEO of Sonoma Pharmaceuticals.

For more information, or to pre-order our pulse lavage irrigation treatment solution in Europe, please contact info.europe@sonomapharma.com.

About Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions, animal health care and non-toxic disinfectants. The company’s products reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner. In-vitro and clinical studies of hypochlorous acid (HOCl) show it to have impressive antipruritic, antimicrobial, antiviral and anti-inflammatory properties. Sonoma’s stabilized HOCl immediately relieves itch and pain, kills pathogens and breaks down biofilm, does not sting or irritate skin, and oxygenates the cells in the area treated, assisting the body in its natural healing process. The company’s products are sold either directly or via partners in 55 countries worldwide and the company actively seeks new distribution partners. The company’s principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com. For partnership opportunities, please contact busdev@sonomapharma.com.

Forward-Looking Statements

Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the “company”). These forward-looking statements are identified by the use of words such as “continue,” “develop,” “anticipate,” “expect” and “expand,” among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company’s business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company’s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company’s products will not be as large as expected, the company’s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company’s cash needs, fund further development, as well as uncertainties relative to the COVID-19 pandemic and economic development, varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company’s filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.

Sonoma Pharmaceuticals™ and Microcyn^® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.

Media and Investor Contact:

Sonoma Pharmaceuticals, Inc.

ir@sonomapharmaceuticals.com

SOURCE: Sonoma Pharmaceuticals, Inc.

Swift’s AI-powered wound imaging technology shown to improve quality of care and costs to manage complex patients

June 01, 2023 09:00 AM Eastern Daylight Time
TORONTO–(BUSINESS WIRE)–Swift Medical, a digital health technology company focused on improving clinical and economic outcomes in wound care, today announced proven outcomes from more than 20 million wound assessments captured with Swift’s leading, AI-powered wound care platform. Deployed in nearly 4,000 healthcare facilities across North America, Swift’s technology has been shown to speed up wound healing by 37%, reduce wound prevalence and hospitalizations by 35% and 14%, respectively, and reduce hospital length of stay by 62%.

“We are proud to share the incredible impact our technology is having on the millions of patients living with wounds – one of today’s most expensive and overlooked threats to patients and our overall healthcare system”

Tweet this
“We are proud to share the incredible impact our technology is having on the millions of patients living with wounds – one of today’s most expensive and overlooked threats to patients and our overall healthcare system,” said Brian Litten, CEO of Swift Medical. “These outcomes demonstrate the impact of having the most powerful wound image dataset in the world and its ability to deliver high quality wound care with reduced costs.”

The Swift Skin & Wound mobile application enables any mobile device to be equipped with AI-powered imaging capabilities to capture clinically validated, high-precision 3D images, measurements, and other clinical data. The imaging captured at the point of care enables real-time, at-risk patient monitoring, proactive decision-making, and remote wound consultations, reducing the time and cost spent evaluating wounds to create a more efficient wound care experience for both clinicians and patients.

Today, more people suffer from chronic wounds than those with breast cancer, colon cancer, lung cancer, and leukemia combined. Despite this costly, growing problem, the current standard of care is outdated and highly inaccurate. Clinicians typically receive less than 10 hours of formal education and rely on paper rulers for measurements and cotton swabs for depth assessment. This inefficient and ineffective approach is both painful for patients and leads to poor diagnostic accuracy, prolonged healing, and inappropriate selection of therapies, putting patients at greater risk for readmission, longer lengths of stay and higher care costs.

With its advanced analytics and proven outcomes, Swift is now poised to partner with health plans and risk-bearing providers to deliver high quality, value-based wound care at scale.

About Swift Medical

Swift Medical is the global leader in digital wound care. We are headquartered in Toronto, with operations expanding across the U.S. and Canada. Our mission is to make empathy-driven wound care ubiquitous through AI-powered diagnostic technology. We are the trusted wound technology partner of more than 4,000 healthcare facilities in North America across the continuum of care. Our solutions empower healthcare providers to deliver standardized, accessible and equitable wound care for every patient – with advanced, high-precision imaging, compliant documentation, clinical analytics and remote care. To learn more about Swift Medical, visit us at www.swiftmedical.com.

Contacts
Media

David Mannion
416-303-8020
david.mannion@swiftmedical.com